



# Interactions Between the Neuroendocrine System and T Lymphocytes in Diabetes

Luz Andreone, María Laura Gimeno and Marcelo J. Perone\*

Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) – CONICET – Instituto Partner de la Sociedad Max Planck, Buenos Aires, Argentina

## OPEN ACCESS

### Edited by:

Daniella Areas Mendes-Da-Cruz,  
Fundação Oswaldo Cruz  
(Fiocruz), Brazil

### Reviewed by:

Denis Richard,  
Laval University, Canada  
Licio A. Velloso,  
Universidade Estadual de  
Campinas, Brazil

### \*Correspondence:

Marcelo J. Perone  
peronemj@gmail.com

### Specialty section:

This article was submitted to  
Neuroendocrine Science,  
a section of the journal  
Frontiers in Endocrinology

**Received:** 30 December 2017

**Accepted:** 20 April 2018

**Published:** 17 May 2018

### Citation:

Andreone L, Gimeno ML and  
Perone MJ (2018) Interactions  
Between the Neuroendocrine System  
and T Lymphocytes in Diabetes.  
*Front. Endocrinol.* 9:229.  
doi: 10.3389/fendo.2018.00229

It is well established that there is a fine-tuned bidirectional communication between the immune and neuroendocrine tissues in maintaining homeostasis. Several types of immune cells, hormones, and neurotransmitters of different chemical nature are involved as communicators between organs. Apart of being key players of the adaptive arm of the immune system, it has been recently described that T lymphocytes are involved in the modulation of metabolism of several tissues in health and disease. Diabetes may result mainly from lack of insulin production (type 1 diabetes) or insufficient insulin and insulin resistance (type 2 diabetes), both influenced by genetic and environmental components. Herein, we discuss accumulating data regarding the role of the adaptive arm of the immune system in the pathogenesis of diabetes; including the action of several hormones and neurotransmitters influencing on central and peripheral T lymphocytes development and maturation, particularly under the metabolic burden triggered by diabetes. In addition, we comment on the role of T-effector lymphocytes in adipose and liver tissues during diabetes, which together enhances pancreatic  $\beta$ -cell stress aggravating the disease.

**Keywords:** T lymphocytes, inflammation, insulin resistance, adipose, muscle, liver, cytokines

## INTRODUCTION

Pioneering work in the 1980s provided the first evidence of the cross-talk between the neuroendocrine and immune systems (1–4). It is now well established that there is a fine-tuned bidirectional communication between these tissues in maintaining homeostasis. Several types of immune cells, hormones, and neurotransmitters of different chemical nature are involved as communicators between organs influencing immune development and function (5, 6). Additionally, it has been described that T lymphocytes apart of being key players of the adaptive arm of the immune system, are involved in the modulation of metabolism in several tissues in health and disease (7–13).

Diabetes is a highly prevalent endocrine-metabolic disease with a constant growing rate, affecting nearly half a billion people worldwide (14). It is characterized by an imbalance in glucose homeostasis, which result mainly from lack of insulin production in the pancreas [type 1 diabetes (T1D)] or insufficient insulin production and peripheral insulin resistance [type 2 diabetes (T2D)] both influenced by genetic and environmental components.

In this Review, we discuss existing data about the role of the adaptive arm of the immune system in the diabetes pathophysiology; including the action of several hormones and neurotransmitters influencing on central and peripheral T lymphocytes development and maturation, particularly under the metabolic burden triggered by diabetes. In addition, we comment on the role of T-effector

lymphocytes in peripheral tissues during diabetes, which together enhance pancreatic  $\beta$ -cell stress aggravating the disease.

## THE ROLE OF T CELLS IN THE PATHOGENESIS OF T1D

Type 1 diabetes is a T cell-mediated autoimmune disease that selectively destroys insulin-producing  $\beta$ -cells. The key roles for both CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the immune response that drives T1D have been extensively described (15, 16). It is now widely accepted that endogenous and/or exogenous initiating factors, operating on a genetic susceptibility background and permissive environmental framework, are necessary for the development of autoreactive T lymphocytes that infiltrate pancreatic islets (insulinitis) (17).

While the association of class II HLA genes polymorphisms with T1D risk has been known for over 40 years (18), recent single-nucleotide polymorphisms (SNPs) genotyping technologies allow the description of many additional T1D susceptibility genes (19–21). Intriguingly, most of these genes are coding for cytokines, cytokine receptors, and factors that regulate T cell differentiation, suggesting that control of T cell identity may be an important element of the genetic contribution to disease susceptibility and onset.

The process of T cell differentiation that takes place in the thymus is regulated by many molecules such as hormones, neuropeptides, and neurotransmitters involving both endocrine and paracrine signaling pathways (6). A variety of peptide and nonpeptide hormones modulate the proliferation, differentiation, migration, and apoptosis of developing thymocytes. The dysfunction in the hormonal control of T cell differentiation is associated with the development of diseases that are influenced by immune cells, including diabetes.

Currently, there is a wide consensus that T1D is a Th1-mediated pathology and INF- $\gamma$  is implicated as the main driver cytokine of the process of autoimmune islet destruction; meanwhile, Th2 cell-type would play a protective role (22–29). However, not all emerging data from mouse models and patients are consistent with the dominance of a Th1 response in T1D; multiple additional T cell differentiation phenotypes are now recognized with distinct functions (30, 31).

The role of Th17 lymphocytes in T1D is not fully understood. Murine models and human studies suggest that IL-17 is upregulated in the early stages of diabetes development but it is still not clear if this cytokine, or indeed if the Th17 subset, is necessary for disease (32–38). It was shown that genetic IL-17 silencing had no effect and did not protect NOD mice from spontaneous autoimmune diabetes (39). Some studies suggested that an increase of T cells co-expressing INF- $\gamma$  and IL-17 could be a feature of T1D development (36, 40–42). Several types of cells of the immune system, attracted by signals from the islets, contribute to the selective  $\beta$ -cell death through the release of cytotoxic inflammatory cytokines, such as IL-1 $\beta$ , INF- $\gamma$ , and TNF- $\alpha$  (43, 44). Recent studies performed in human  $\beta$ -cells suggested that pancreatic IL-17 contributes to the pathogenesis of T1D by two mechanisms, exacerbating  $\beta$ -cell apoptosis and increasing local

production of chemokines by islets exposed to pro-inflammatory cytokines (e.g., IL-1 $\beta$  + INF- $\gamma$  and TNF- $\alpha$  + INF- $\gamma$ ) (45). In a study of children in various phases of diabetes-associated autoimmunity and clinical disease upregulation of IL-17 and Th1/Th17 plasticity in peripheral blood were observed in stages of advanced  $\beta$ -cell autoimmunity and impaired glucose tolerance and clinical T1D (42). Activated Th17 immunity was not observed in patients with early  $\beta$ -cell autoimmunity, indicating that Th17 may be a marker of late preclinical autoimmune diabetes which correlates with impaired  $\beta$ -cell function. Analysis of pancreatic lymph nodes in T1D patients showed higher frequency of Th17 cells in comparison with non-diabetic controls (46). The consolidation of Th17 cells as part of T1D pathophysiology focused attention on additional cytokines, outside of those associated classically with the Th1/Th2 paradigm (INF- $\gamma$  and IL-4, respectively).

IL-21 is a pleiotropic cytokine produced mainly by T follicular helper (Tfh) cells, Th17 cells, and natural killer (NK) cells. Although it has been demonstrated that IL-21 enhances Th17 differentiation and it can be produced by Th17 cells to exert autocrine feedback (47, 48), existing data indicated that the role of IL-21 in the development of diabetes is more than just an effect on Th17 differentiation. Preclinical studies performed in the NOD mice demonstrate that the IL-21 pathway is critical for disease development (49–51). It acts in a paracrine and autocrine fashion affecting the differentiation and function of several immune cell types in the context of T1D, including CD4<sup>+</sup> and CD8<sup>+</sup> T cells, NK cells, B cells, macrophages, and dendritic cells (52, 53). Moreover, transgenic overexpression of IL-21 in the pancreatic islets results in autoreactive T cell infiltration and  $\beta$ -cell apoptosis in C57BL/6 mice, a strain free of any kind of autoimmunity signs (54).

As aforementioned, IL-21 is the signature cytokine for Tfh cells, the T lymphocyte subset that is specialized in providing help for B cell antibody production (55). Islet autoantibodies are the best currently available biomarkers to detect ongoing autoimmune process and T1D development risk (56). The production of such antibodies by autoreactive B cells is largely dependent on the function of Tfh cells. By means of an unbiased microarray approach and flow cytometry assay, a recent study assessed T cell differentiation in a mouse model of spontaneous autoimmune diabetes revealing that islet-specific T cells responding to pancreatic antigens show mainly the characteristic features of differentiated Tfh cells (57). Also, adoptive transfer of T cells with a Tfh phenotype from diabetic animals is highly efficient at inducing diabetes to murine recipients. Furthermore, peripheral memory CD4<sup>+</sup> T cells from patients with T1D expressed elevated levels of Tfh cell markers (57). In accordance, an increase in peripheral blood Tfh cells has also been reported in three T1D patient independent cohorts, one of which comprised exclusively new-onset patients (58–60).

Interleukin-2 (IL-2) is critical for maintaining the function of the CD4<sup>+</sup> regulatory T cells (Tregs), which in turn regulate autoreactive CD4<sup>+</sup> effector T cells (Teffs) to prevent autoimmune diseases, such as T1D (61, 62). The involvement of the IL-2 pathway in the physiopathology of T1D first emerged from NOD mice; a reduced IL-2 production by the susceptibility allele (NOD disease-associated SNPs in IL-2 promoter) led to a consequent

reduction of Treg function (63, 64). In humans, certain SNPs of the IL-2 receptor gene, *IL2RA*, encoding the  $\alpha$  subunit (CD25) as well as of other genes in the IL-2 pathway, were identified as susceptibility determinants for T1D (65–68). Accordingly, an attenuated IL-2/IL-2R signaling was observed in Treg and Teff cells of T1D patients (69). In a clinical study with recently diagnosed T1D subjects, treatment with low doses of recombinant human IL-2 successfully induced a 10–20% increase in circulating Tregs whereas reduced Teffs, NK cells, and eosinophils (70); these findings lay the groundwork for the potential therapeutic use of rhIL-2 for treating T1D.

At present, emerging evidence suggests that pancreatic-resident Treg subsets have unique effects on the suppression of immune responses in T1D (71). Those distinguishable Treg subpopulations that reside in tissues exhibit special phenotype and function in response to local signals, thereby promoting tissue homeostasis (72). Among those special Treg subsets found in pancreatic tissues and pancreatic lymph nodes involved in preventing inflammation during T1D are: IL-10 secreting ICOS<sup>+</sup> Tregs (73, 74), CXCR3<sup>+</sup> Tregs (75), and TGF- $\beta$ -expressing Tregs (76).

In summary, several studies regarding T cell differentiation in T1D clearly demonstrated not only the role of Th1 cells but also the possible involvement of other kind of T-effector cells co-expressing IFN- $\gamma$  and IL-17, IL-21 producing T cells such as Tfh cells as well as circulating and pancreatic-resident Tregs.

## T CELLS CONTRIBUTION TO ADIPOSE TISSUE INFLAMMATION AND OBESITY-ASSOCIATED DIABETES

Type 2 diabetes is a metabolic disease characterized by hyperglycemia resulting from either or both impaired  $\beta$ -cell insulin secretion and increased peripheral insulin resistance; particularly in muscle, liver, and fat (77). The pathogenesis of T2D is complex, it is a multifactorial disease that involves behavioral and environmental factors modulating T2D risk alleles in multiple genes. The pancreatic islets respond to the decrease in insulin-stimulated glucose uptake by enhancing their  $\beta$ -cell mass and insulin secretory activity. When  $\beta$ -cell function can no longer compensate for the prevailing insulin resistance, impaired glucose tolerance and T2D develop.

$\beta$ -cell dysfunction precedes diabetes, and endoplasmic reticulum (ER) stress contributes to insulin secretory failure.  $\beta$ -cells are particularly susceptible to ER stress due to the high rate of insulin demand in response to rapid changes in glycemia levels. Many environmental factors, including inflammatory cytokines (78), reactive oxygen species (ROS) (79), and viral infections (80), may induce ER stress in  $\beta$ -cells associated with T1D triggering. Dysfunctional  $\beta$ -cells of NOD mice show feature ER stress before overt diabetes (81) and strategies directed to ameliorate ER stress may have therapeutic potential (82). Also, several lines of evidence link inflammation-associated obesity, ER stress, and T2D. The association of ER stress and T2D has been reviewed recently (83).

Inflammation was first linked to insulin resistance and T2D in the early 1990s; an induction of TNF- $\alpha$  expression was systemically

and locally observed in adipose tissue from four different rodent models of obesity and diabetes (84). Since then, several studies have described elevated circulating levels of diverse inflammatory factors, such as acute-phase proteins, cytokines, and chemokines in patients with T2D (85–88). Currently, T2D is recognized as a chronic, low-grade inflammatory disease with involvement of pro-inflammatory cytokines and immune cells, including B and T cell subsets as pathogenic mediators (89, 90).

The inflammatory process observed in T2D is usually linked to obesity, a critical risk factor for the disease. Moreover, altered lipolysis in response to over nutrition and rapidly expanding adipose tissue results in elevation of pro-inflammatory saturated free fatty acids (FFAs). FFAs trigger metabolism-associated inflammation through toll-like receptors (TLRs), particularly TLR2 and TLR4, activating signaling pathways that lead to local adipose tissue infiltration by immune cells and systemic insulin resistance (91). The activation of TLR2/4 induces the production of inflammatory cytokines by dendritic cells, macrophages, endothelial cells, and pancreatic islets, as well. During diabetes, high circulating levels of glucose, FFAs, and pro-inflammatory cytokines contribute to insulin resistance and alterations in the immune system (91). Of note, the TLR2/TLR4 expression levels are upregulated in obese individuals (92). Moreover, TLR2- and TLR4-deficient mice are protected from the metabolic undesirable effects of high-fat diet (93) and experiments administering TLR2 antisense-oligonucleotides to high-fat-fed mice recovered insulin sensitivity in adipose tissue (94). Furthermore, nutrient excess may also induce local inflammation in the pancreatic islets (12, 95–97). Tissue inflammation has been detected in pancreatic islets of T2D patients, along with increased levels of cytokines and chemokines. Moreover, all T2D animal models investigated to date display some degree of insulinitis (98, 99). TLR2/4 ligands are central in macrophages activation and consequent reduction of insulin secretion from pancreatic  $\beta$ -cells mainly by action of IL-1 $\beta$  and IL-6 on decreased insulin gene expression (100). Also, downstream MyD88-dependent and independent signaling pathways of FFAs-activated TLR2/4 induce differential gene expression and cellular responses leading to islet inflammation and  $\beta$ -cell dysfunction [reviewed in Ref. (101)].

Macrophages are the major immune cell type in adipose tissue, and its relative abundance increased from 5% in lean subjects to a level of up to 50% in obese patients. Moreover, the increase in number is accompanied by an evolution from the anti-inflammatory M2- to the pro-inflammatory M1-phenotype (102); adipose tissue macrophages (ATMs) produce a significant proportion of the inflammatory factors that are upregulated during obesity (95, 96, 103). Therefore, first studies on inflammatory regulation of T2D have been focused on the innate arm of the immune system. However, more recent studies suggest that adaptive immune cells, especially T lymphocytes, generally accumulate in obese adipose tissue in parallel with macrophages and also play a pivotal role in the pathophysiology of T2D (104). Moreover, studies in a mice model of T2D suggest that the accumulation of T lymphocytes in the adipose tissue might occur even before the arrival of macrophages (105).

T cells play a key role during the sequence of events that lead macrophage adipose tissue infiltration. In particular, CD8<sup>+</sup> T cells

are activated in adipose tissue which in turn, primer the recruitment and activation of macrophages within this tissue. In fact, infiltration of CD8<sup>+</sup> effector (CD62L<sup>-</sup> CD44<sup>+</sup>) T lymphocytes are described as one of the earliest events during the development of adipose tissue inflammation in mice due to obesity caused by *ad libitum* access to a high-fat diet (106). CD8<sup>+</sup> T infiltration takes place in obese individuals too, as the expression of CD8A in subcutaneous adipose tissue was found elevated in comparison with lean subjects. Interestingly, CD8<sup>+</sup> T lymphocytes not only precede adipose tissue infiltration by other immune cells, they are also required for the maintenance of inflammation in obese adipose tissue, since CD8<sup>+</sup> T depletion attenuated adipose tissue inflammation and ATMs recruitment, and ameliorated insulin resistance and glucose intolerance in obese mice. CD8<sup>-null</sup> mice fed a high-fat diet show moderate imbalance of glucose homeostasis. In this respect, gain of function experiments in where CD8<sup>+</sup> T cells were administered into obese CD8<sup>-null</sup> mice aggravate glucose intolerance and insulin resistance, reinforcing the notion that CD8<sup>+</sup> T cells are essential for M1 macrophage infiltration and subsequent inflammation in diet-induced obese mice (106).

Visceral adipose tissue (VAT) inflammation involves a complex communication network between different T cell subpopulations expanded by factors that drive differentiation into several kinds of pro-inflammatory effectors. Adipose tissue T cell populations changed with increasing obesity in mice, and an increase in the ratio of CD8<sup>+</sup> to CD4<sup>+</sup> was reported by various research groups (9, 10, 106, 107). Particular T cell subpopulations play key roles in glucose homeostasis in human and mice. Winer and colleagues reported the importance of VAT resident CD4<sup>+</sup> T lymphocytes as modulators of insulin sensitivity in mice under diet-induced obesity; glucose homeostasis was compromised when pathogenic IFN- $\gamma$ -secreting Th1 cells accumulated in adipose tissue and overwhelmed the static numbers of Th2 and Treg cells. In fact, total absence of INF- $\gamma$  improved insulin resistance in obese INF- $\gamma$  KO mice in comparison with control animals having the same diet (108). It was reported that Rag1<sup>-</sup> mice, known to be deficient in lymphocytes, developed a T2D phenotype on a high-fat diet, and when adoptively transferred with CD4<sup>+</sup> T cells but not CD8<sup>+</sup> T cells, normalized glucose tolerance; in particular Th2 signals from the transferred CD4<sup>+</sup> T cells were crucial in the protective effect (10). Clinical studies have confirmed the abundant infiltrate of Th1, Th2, and Th17 CD4<sup>+</sup> T cells, as well as IFN- $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells in adipose tissue of healthy overweight and obese humans (109); pro-inflammatory Th1, Th17, and IFN- $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells were markedly increased in VAT relative to subcutaneous adipose tissue. Also, McLaughlin and colleagues confirmed the positive correlation between the relative dominance of Th1 vs Th2 responses in the adipose tissue and peripheral blood and insulin resistance.

A distinctive T cell subpopulation which infiltrates VAT, in a B-lymphocyte dependent way, has been recently identified and resembles senescence-T cells that show up in secondary lymphoid organs with age (110). Phenotypically they are distinguished by expression of CD44<sup>hi</sup>CD62L<sup>lo</sup>CD153<sup>+</sup>PD-1<sup>+</sup> on the surface of CD4<sup>+</sup> T cells and their feature characteristic is the large production of pro-inflammatory osteopontin upon T cell receptor (TCR) stimulation in parallel with compromised IFN- $\gamma$

and IL-2 secretion. Moreover, they expressed increase senescence associated markers, such as  $\beta$ -gal,  $\gamma$ -H2AX, and *Cdkn1a/Cdkn2b*. This osteopontin-expressing T cells linked visceral adiposity with immune aging (110).

Invariant natural killer T (iNKT) cells are innate T cells involved in inflammatory responses. Adipose tissue-resident iNKT cells protect against obesity and metabolic disorder reducing inflammation in obese individuals (111); they are enriched in human adipose tissue and their number is reduced in obesity (112). iNKT cells express semi-invariant CD1d-restricted TCRs that recognize glycolipid antigens on major histocompatibility complex-like molecule CD1d (113, 114). Huh et al. reported that the absence of CD1d in adipocytes aggravates inflammation in adipose tissue and insulin resistance in obesity suggesting that adipose CD1d is a central activator of adipose iNKT cells. Activated iNKT cells would stimulate counter regulation of inflammation leading to reduced pro-inflammatory responses and insulin resistance in obesity (115).

The relationship between T2D and Th17 cells has also been studied (116). Obesity has been shown to promote expansion of peripheral or adipose tissue-resident IL-17-producing T cells, in human and mice models. In humans, peripheral Th17 cells are increase in T2D patients (117) and positively correlated with body mass index (BMI) but not in metabolically healthy obese subjects (118). Interestingly, T cells from obese T2D donors produced more IL-17 than that from non-diabetic counterparts and this production correlates with T2D severity (118). In diet-induced obese mice an IL-6-dependent expansion of the Th17 T cell pools was observed (119). Specific adipose tissue dendritic cells isolated from obese animals and humans were associated with the differentiation of Th17 cells *in vitro* (120). Studies performed by Zúñiga and colleagues showed an *in vitro* effect of IL-17 on differentiated adipocytes, impairing glucose uptake; *in vivo*, IL-17 deficiency enhanced glucose tolerance and insulin sensitivity in young mice (121).

The role of Treg cells in the maintenance of self-tolerance and the suppression of potentially autoreactive T cells is well known. However, the importance of Treg cells in metabolism has been recognized when it was found that lean adipose tissue enriched in Treg cells (~50% of the CD4<sup>+</sup> T cell compartment) controls metabolic status. Indeed, Treg cells in adipose tissue of lean mice provide anti-inflammatory signals to prevent tissue inflammation. Interestingly, Treg cell proportion in the abdominal fat decreases dramatically with obesity (9, 10, 122) resulting in fat tissue inflammation and insulin resistance. Moreover, Feuerer et al. demonstrated that cytokines differentially synthesized by fat-resident Tregs directly affected the synthesis of inflammatory mediators and glucose uptake by cultured adipocytes. Winer et al. associated this Treg mediated protection to the production of IL-10 in ATMs and the restraint of pro-inflammatory macrophage activity, which improves insulin sensitivity.

In accordance, studies in humans showed that the relative proportion of Treg cells in visceral and subcutaneous fat decreased in patients with T2D and negatively correlated with BMI (9, 118) and that there is a decrease in Treg to Th17 and Th1 cell ratios (117). A recent study add complexity to the Treg role on the mechanisms underlying insulin resistance, supporting the concept that



age-associated and obesity-associated IR are driven by distinct adipo-immune populations (123). Bapat and colleagues showed that a particular subset of fat-resident regulatory T cells (fTreg cells) accumulate in VAT as a function of age but not obesity. Additionally, the authors suggest that fTreg cells are functionally distinct from splenic Tregs; while certain canonical genes are similarly expressed, they have discrete expression signatures (i.e., higher expression levels of PPAR $\gamma$  and IL-33 receptor, ST2). Taking advantage of the high expression of ST2 on the surface of fTreg cells, Bapat and co-workers deplete fTreg cells by means of anti-ST2 administration. Interestingly, selective depletion of fTreg cells increases adipose tissue insulin sensitivity implicating these cells as drivers of age-associated insulin resistance (123). Contrary, *in vivo* stimulation of fTreg cells expansion within adipose tissue by treatment with IL-33 decreases insulin sensitivity. All these data suggest that distinct pathophysiologies undergo obesity and age-associated insulin resistance and support the notion that adipo-resident immune cells play a central role in adipose tissue glucose regulation and consequently, whole-body glucose homeostasis in mice.

Interestingly, recent evidences in mice and human suggested that the adipose tissue inflammation associated with obesity, in particular the T cell imbalance, and the impairment in insulin sensitivity, persist even after weight reduction (124, 125). It remains to be elucidated the precise mechanistic pathways of glucose regulation by T cells in human beings.

In summary, the evidence involving the role of T cells in adipose tissue inflammation and insulin resistance suggests that the interplay between T cells, macrophages, and adipocytes is essential. These cells communicate each other in the local adipose tissue environment to activate a sequence of events leading to an inflammatory state. It has been described the role of CD8<sup>+</sup> T cells, Th1 and Th17 cells contributing to the obesity-induced insulin resistance phenotype, whereas Th2 cells and Tregs would play a protective role. However, the identity of the trigger that initiates T lymphocyte infiltration within adipose tissue in obesity still remains unknown.

## LIVER AND GASTROINTESTINAL RESIDENT T CELLS IN METABOLIC DISORDERS

The liver participates in immunological responses and hepatocytes are also recognized as active immunological mediators among other well-known intrahepatic immune cells (126). There is a subset of innate-like T cells, named mucosal-associated invariant T (MAIT) cells, that recognizes small molecules presented on the non-polymorphic MHC-related protein 1 (MR1) by antigen-presenting cells and express a semi-invariant TCR (127). Like iNKT cells, these non-conventional T cells exhibit restricted TCR diversity recognizing metabolites on MR1 and play a major role in host protection from intracellular pathogens. MAIT cells are scarce in lymphoid tissues, comprising a high proportion of the total intrahepatic and gastrointestinal tract T cells population in humans, having a relevant role as an innate immune barrier against microbial invasion. However, their role in diseases begins

to be clarified recently. Interestingly, MAIT cells activate under changes in the composition of gut microbiota and home to inflamed tissues. Magalhaes et al. reported for the first time the existence of MAIT cells abnormalities in severe obese and T2D patients (128). Both, obese and T2D patients showed a decreased in the number of circulating blood MAIT cells as well as dramatic changes in their functionality, i.e., an activated phenotype associated with high Th1- and Th17-type cytokines production. In obese individuals, an elevated number of MAIT cells in inflamed adipose tissue was found suggesting their recruitment from circulation.

Many studies have linked the microbiota, gut integrity, and metabolic disorders. MAIT cells might play a role involving the immune system as a fundamental part of these complex interactions. Recently, Rouxel et al. described that MAIT cells, exhibiting high production of granzyme B and pro-inflammatory cytokines, might directly kill  $\beta$ -cells in humans and NOD mice as well (129). As in the case for T2D patients, a reduced frequency of MAIT cells in peripheral blood of children with recent diagnosis of T1D was described, but not in those who are suffering from the disease for a long period of time. All these evidences highlight the role of MAIT cells in the maintenance of homeostasis within the complex interplay between mucosal integrity and normal islet responses. It would be interesting to investigate the functionality of gastric-resident MAIT cells in gastroparesis, a well-recognized complication of diabetes, since it has been demonstrated a connection between these cells with inflammatory bowel disease (130).

Although the mechanisms triggering and sustaining autoimmunity are not fully understood, the interaction of the intestinal environment with microbiota and, its epithelial integrity play a role in the development of T1D, and the disease in NOD mice (131, 132). A recent paper highlights the relevance of intestinal IL-10-producing type 1 regulatory T (Tr1) cells in the control of Tregs and development of diabetes (133). Increased differentiation of Tr1 cells may account by IL-27 and TGF- $\beta$  action on intestine. These Tr1 cells have the ability to migrate to islets where they can suppress diabetogenic T cells *via* IL-10 signaling. Moreover, gut microbial metabolites augment the number and function of Treg cells, limiting the frequency of autoreactive T cells and protecting against autoimmune diabetes in NOD mice (134).

## SKELETAL MUSCLE RESIDENT T CELLS AND GLUCOSE HOMEOSTASIS

Skeletal muscle is the predominant tissue of insulin-mediated glucose uptake in the postprandial state in humans (135); moreover, lipid accumulation in this tissue is associated with insulin resistance. Muscle insulin resistance is a major factor in the etiology of the metabolic syndrome and T2D (136). The increase in macrophages number within skeletal muscle has been associated to metabolic risk markers and insulin resistance in humans and mice (137, 138). However, little is known about the contribution of T cells infiltration to skeletal muscle inflammation and insulin resistance. Skeletal muscle T cells infiltration occurs in high-fat diet-fed mice (139). T cells localize within skeletal muscle in

intermuscular and perimuscular adipose tissue suggesting that they might play a role in obesity-induced skeletal muscle inflammation and insulin resistance (13). Within skeletal muscle T cells polarized into pro-inflammatory INF- $\gamma$ -secreting Th1-type inducing myocyte inflammation and insulin resistance through activation of JAK/STAT pathways, while Treg cells diminish in number. Interestingly, TCRb<sup>-/-</sup> (TCR beta chain null) diet-induced obese mice show reduced skeletal muscle inflammation partially attributable to the lack of Th1 cells, confirming the role of T cells in skeletal muscle inflammation (139). Signals such as chemokines/cytokines/adhesion molecules that induce T cells infiltration into skeletal muscle are not yet identified. However, CD11a<sup>-/-</sup> mice exhibited low inflammatory gene expression in VAT (140).

Administration of JAK1/JAK2 inhibitors *in vivo* reduces T cells infiltration within skeletal muscle and attenuates insulin resistance (13). Although there is no information, to our knowledge, about the presence of T cells infiltration in skeletal muscle in T1D, it has been described that a particular subpopulation of CD4<sup>+</sup> T cells is associated with cachexia in NOD mice (141). In T2D, the level of transcriptome and proteome expression of activated T cells and muscle differ relative to non-diabetic controls (142). T cells, in particular Treg subsets, have homeostatic functions in muscle tissue repair regulating both the inflammatory response, by promoting the switching from M1 to M2 macrophages, and the activation of myogenic stem cells (143). However, further investigation will be required to choose any T lymphocyte subsets as potential targets for improving cachexia in diabetes.

## HORMONES, NEUROPEPTIDES, AND NEUROTRANSMITTERS MODULATE T CELL FUNCTION IN DIABETES

T cell capacity to respond against foreign antigens while avoiding reactivity to self-peptides is mainly determined by cellular selection of developing T cells in the thymus (144). Positively selected cells migrate to the peripheral lymphoid organs and target tissues; however, extrathymic pathways of T cell differentiation have also been demonstrated to contributing to the generation of a wide functional spectrum of TCR repertoire.

Several hormones and neurotransmitters impact thymic microenvironment and peripheral tissues affecting T cell development in health and disease (6). In particular, numerous studies performed in human and mice models analyzed the neuroendocrine-immune systems relationship under the metabolic burden of diabetes.

### Growth Hormone (GH)—Insulin-Like Growth Factor-1 (IGF-1)

Growth hormone exerts pleiotropic functions modulating from carbohydrate, protein, and fat metabolism to the immune response (145). It is secreted by the anterior pituitary and also produced by immune tissues thereby acting in an autocrine/paracrine manner on immune cells (146).

It was reported that a single point mutation within the DNA binding domain of Stat5b, a central transcription factor

downstream GH receptor, is a key molecular defect in NOD mice that limits Foxp3 expression in Treg cells (147, 148). Transgenic NOD mice overexpressing GH show normal glycemia throughout their lives; histochemical analysis of the pancreas revealed the development of peri-insulitis, but showed little or no islet infiltration or  $\beta$ -cell destruction (149). The authors demonstrated that this protective outcome involves several GH-mediated mechanisms on T cells, altering cytokine environment against a Th1 response, maintaining the activity of Treg cell subsets, and affecting Th17/Th1 plasticity. Additionally, sustained GH expression positively influenced  $\beta$ -cell viability.

Conversely, human studies reported that the incidence of T1D during GH replacement therapy in GH-deficient children was comparable with that of the general population (150–152) and described an association of GH treatment with disturbances on carbohydrate metabolism. The hyperglycemic effect of GH has been well-described mainly due to their action on liver, muscle, and adipose tissue (153–155). It is known that many of the GH effects are mediated by the production of IGF-1; thyrocytes produce and release IGF-1 and also express its cognate receptor (156).

Several studies propose IGF-1 as a key factor able to induce protection from T1D. Human recombinant IGF-1 administration in NOD mice reduces the severity of insulitis and the incidence of autoimmune diabetes (157–159). The protective T cell-mediated effects of IGF-1 on T1D arose more recently. Anguela and colleagues showed that plasmid-delivered overexpression of IGF-1 in the liver prevents the development of hyperglycemia in a mice model of T1D; decreasing pancreatic infiltration, reducing apoptosis, and increasing replication of  $\beta$ -cell. In this experimental model, they observed an increase of intra-pancreatic Treg cell numbers and proposed an indirect effect mediated by IL-7-producing dendritic cells that improved Treg survival or by the conversion of conventional T cells into Tregs by TGF- $\beta$  secreted from the liver (160). In a latter study, it was demonstrated that IGF-1 directly stimulates Treg cells proliferation *in vitro* in both mouse and human. Moreover, *in vivo* IGF-1 treatment via continuous delivery specifically stimulated proliferation of Treg but no other T cell subtypes and exerted protective action against autoimmune diabetes in two mice models [NOD and multiple low-dose streptozotocin (STZ) injections in C57BL/6J mice] (161). It is noteworthy that the protective effect of IGF-1 treatment might be also exerted at the  $\beta$ -cell level (162–164).

### Glucocorticoids (GCs)

Glucocorticoids are endogenous modulators of several biological processes including regulation of metabolism and stress response, and development of the immune system. In particular, GCs broadly affect T cell differentiation and function (165) with positive or negative effects depending on the dose at which they are exposed (166). Synthetic GCs are widely used for their immunosuppressive and anti-inflammatory properties to treat several immune disorders and preventing transplant rejection (167). Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes in a rat model by downmodulating Th1 responses and restoring the balance between

CD8<sup>+</sup> T and Treg cells (168). However, the well-described severe side metabolic effects, such as osteoporosis, hypertension, and insulin resistance, induced by the chronic administration of GCs limits its therapeutic use for autoimmune diabetes (169). It is widely recognized the inhibitory action of GCs, when pharmacologically administered *in vivo*, on the proliferation of several human subpopulation of Ag- and mitogen-stimulated T cells (170). Mechanistically, the underlying inhibitory effects have been attributed to the ability of GCs to restrain gene expression of cytokines. In this respect, IL-2 has been indicated as the principal growth factor for T lymphocyte proliferation (171). However, under physiologic concentrations GCs show contrasting effects promoting TCR-stimulated T cell proliferation (172). CD4 acts as an important coreceptor during Ag recognition by the TCR, contributes to the assembly of TCR-MHC-II complex and thus, increases the sensitivity of T cell to the Ag presented by MHC-II lowering the amount of Ag required to mount an effective immune response. Corticosterone accelerates the expression of CD4 on T cell membrane (173). It has been reported that physiologic concentration of GCs regulates CD4 expression upon T lymphocyte challenge by Concanavalin A or TCR stimulation. Also, CD8 expression is induced by GCs on activated mature T cells (174). Therefore, TCR triggering induces the expression of CD4 and CD8 on T lymphocytes and physiologic levels of GCs increase this process enhancing T cell activation.

Glucocorticoids affect gene expression by two main GR-dependent and -independent intracellular mechanisms that exert several biological effects. These differential mechanisms have fueled the interest in the study and development of new GR-ligands with dissociative properties combining GCs' anti-inflammatory properties with a reduced side effect profile (175, 176). These particular dissociated GR-ligands hold potential for their use in Th1-mediated immune disorders. Cpda is a dissociating compound which does not stimulate GR response elements-driven gene expression (177). It has been reported that Cpda regulates T cells through inhibition of the master transcription factor T-bet and induction of GATA-3, thus inhibiting Th1 and favoring Th2 response (178).

In pregnant women at risk of preterm delivery, GCs are routinely administered in order to improve fetal lung development and newborn survival (179). The association of increased exposure to cortisol *in utero* (due to stress, pharmacological treatment, or impaired function of 11 $\beta$ -HSD-2) with long-term effects on glucose-insulin homeostasis has been demonstrated in human and animal models (180–183). However, studies regarding the effects of prenatal GCs on the development of autoimmunity are limited. Recently, using a mice model, Tolosa and colleagues demonstrated that prenatal administration of betamethasone increases apoptosis of developing thymocytes and induces changes in the TCR repertoire decreasing the frequency of pathogenic T cells and protecting from T1D development in NOD mice (184, 185). Conversely, an epidemiological study in Danish cohorts indicated the existence of an increased risk for T1D and T2D in young children who received prenatal steroid treatment (186). Under this scenario, a role of prenatal GCs exposure on pancreas development and T cell effects cannot be ruled out (187).

## Ghrelin and Leptin

Peptide hormones known to be involved in the control of eating behavior, glucose metabolism, and energy homeostasis, such as ghrelin and leptin, also exert regulatory effects on the immune system *via* their actions on several leukocytes, including T lymphocytes. Ghrelin and leptin are considered to play mutually antagonistic actions on food intake at the hypothalamic area (188, 189). The interplay between leptin and ghrelin at the level of immune cells was recently recognized. It seems likely in general terms that orexigenic peptides like ghrelin may play a role in promoting endogenous anti-inflammatory responses. On the other hand, anorexigenic agents like leptin might assist inflammation.

Ghrelin is mainly produced by endocrine-like cells in the stomach and released into peripheral blood. Also, the synthesis and secretion of ghrelin by T lymphocytes have been described (190). Human T lymphocytes constitutively express low levels of ghrelin which significantly increase upon cellular activation by stimulated TCR. Moreover, ghrelin enhances proliferation of peripheral CD4<sup>+</sup> T cells and thymic murine T cells upon activation with anti-CD3/-CD8 mAbs and during its administration *in vivo*, respectively (191).

It was shown that ghrelin attenuated age-associated and GC-mediated thymic atrophy, and stimulated thymocyte proliferation in young and old mice *in vivo* through activation of its receptor GHS-R1a (191). Thymus involution with age correlates with lower expression levels of intrathymic ghrelin and its receptor, and exogenous administration of ghrelin partially reversed thymus involution and, consequent improvement of thymic progenitors and mature T lymphocytes (192). In addition, ghrelin action on suppressing inflammation might be attributed to the observed inhibition of T derived pro-inflammatory cytokines expression and Th17 development (190, 193). The acylated form of ghrelin exerts potent inhibitory effects on the expression of pro-inflammatory cytokines, such as IL-1 $\beta$ , TNF- $\alpha$ , and IL-6, as well as adhesion molecules by TCR-stimulated T cells. It has been suggested that these inhibitory actions of acylated ghrelin are mediated by GHS-R1a *via* specific blocking of NF- $\kappa$ B and/or STAT3 signaling (190).

There is also evidence that ghrelin is synthesized by T cells and inhibition of its production by using siRNA resulted in stimulation of INF- $\gamma$ , IL-17 and other chemokines upon TCR ligation indicating that ghrelin might also influence T cell micro-environment regulating immune responses (193). Interestingly, ghrelin downregulates leptin-induced pro-inflammatory Th1 responses (190), suggesting that apart from counteract each other's function at the level of energy homeostasis their interplay might influence T cells function as well. Ghrelin administration delays the development of autoimmune diabetes by reducing islet infiltration in BioBreeding rats; unfortunately, there is absence of information whether this hormone has any effect on diabetogenic T lymphocytes in this setting (194). However, it might be possible the regulation of diabetogenic T cell population through indirect mechanisms such as, an increase in the number or potency of Treg cells due to the reported modulatory effects of ghrelin on monocytes and dendritic cells (190, 195).



Leptin is an adipokine mainly secreted by white adipose tissue, which belongs to the family of the long-chain helical cytokines (IL-2, IL-15, and IL-12) commonly associated with pleiotropic functions. Leptin regulates feeding behavior and metabolism (196), hematopoiesis (197), angiogenesis (198), and reproduction (199). Also, leptin exerts modulatory actions on the immune systems (200). It was shown that leptin induces proliferation and secretion of IL-2 by CD4<sup>+</sup> T lymphocytes in humans and mice (201). In addition, leptin assists Th1 cell-biased immune responses stimulating the secretion of INF- $\gamma$  by T cells (202). Therefore, leptin promotes pro-inflammatory immune responses like the antigen-specific Th1-type directed against  $\beta$  cells observed in T1D. In fact, it has been reported that administration of leptin during early life accelerates the development of autoimmune diabetes in the NOD mice (203). Interestingly, Materese et al. found that circulating leptin peaked soon before the onset of hyperglycemia and spontaneous diabetes in female prone NOD mice. The administration of leptin enhanced the production of INF- $\gamma$  by peripheral T lymphocytes. On the other hand, a mutated version of the leptin-receptor in NOD mice suppresses autoimmune diabetes progression (204). All these evidences point leptin with its permissive action on the development of polarized Th1-type autoimmunity against  $\beta$  cells.

## Insulin

Only sparse data are available regarding the role of insulin on T lymphocytes. It has been reported that insulin infusion resulted in reduction of NF- $\kappa$ B and ROS generation, and increase in I $\kappa$ B in mononuclear cells, all changes characteristic of an anti-inflammatory effect at the molecular level (205). Unfortunately, this study did not address whether there is a similar response to insulin treatment in all mononuclear cells or there is a particular cellular type more sensible to insulin action. Later, it was elucidated that insulin drives T cell differentiation toward an anti-inflammatory Th2-phenotype by mechanisms that involve ERK activation (206). Nevertheless, other study found that in T cells isolated from obese subjects incubation with supra-physiological concentration of insulin did not alter the Th1/Th2 balance suggesting that insulin signaling in lymphocytes is strongly impaired in obesity, shifting T-cell differentiation toward a pro-inflammatory phenotype (207). During diabetes there is a high occurrence of apoptosis in lymphocytes and insulin treatment reduces this effect, suggesting that insulin may act as a pro-survival factor for lymphocytes (208). Moreover, there is evidence in favor of a role of insulin in promoting obesity-associated adipose tissue inflammation (209).

A recent theoretical study simulated how hyperinsulinemia might alter the dynamics of the CD4<sup>+</sup> T regulatory network (210); the analysis showed how high insulin levels affect the differentiation and plasticity of CD4<sup>+</sup> T cells favoring stabilization of inflammatory Th1 and Th17 and reducing the stability of Treg types. In line with this *in silico* observations, it has been demonstrated *in vitro* that Tregs express the insulin-receptor and that high levels of insulin specifically inhibits IL-10 production *via* AKT/mTOR signaling and impairs the ability of Treg cells to suppress TNF- $\alpha$  production by macrophages (211). Moreover, the authors showed that Tregs from the VAT of hyperinsulinemic diet-induced obese mice exhibited a specific decrease in IL-10 production, as well as a

parallel increase in INF- $\gamma$  production; suggesting that hyperinsulinemia may contribute to the development of obesity-associated inflammation *via* modulation of Treg function.

Resting T lymphocytes do not express detectable levels of insulin-receptor; however, after activation its expression is significantly increased (206, 212, 213). A more recent study suggests that upregulation of the insulin-receptor on activated T cells is critical for T cell function and efficient adaptive immune response (214). In conditions of impaired insulin-receptor expression, T-effector activities are diminished resulting in attenuated clinical symptoms in a T-cell-mediated multiple sclerosis model *in vivo* (214). Fischer et al. showed that silencing the insulin-receptor on T lymphocytes disrupts their function, such as reducing cytokine production, proliferation, and migration without affecting thymocytes development. Interestingly, the absence of insulin-receptor affected CD4<sup>+</sup> and CD8<sup>+</sup> T subsets whereas the frequency and potency of Treg cells were unaffected (214).

T lymphocytes use aerobic glycolysis (Warburg effect) upon activation and their increase in glucose demand is facilitated by induction of the insulin-receptor along with GLUT1 (215). Given the critical dependence on glucose upon activation, glycemic status should be considered as a factor affecting T cell function. The diabetic state, where circulating glucose levels are elevated, provides an environment of oxidative stress and activation of the inflammatory pathways. Transgenic expression of Glut1 augmented T cell activation and led to accumulation of readily activated memory-phenotype T cells with signs of autoimmunity in aged mice (216). Increased glucose uptake may lead to excessive T cell activity and accumulation as a result of enhanced T cell activation and/or inhibition of T cell death following stimulation. Moreover, human CD4<sup>+</sup> and CD8<sup>+</sup> T cells differ in the relative use of the metabolic pathways contributing to functional responses. Thus, CD4<sup>+</sup> T subset shows higher basal glycolysis mainly attributed to elevated expression of glycolytic enzymes and CD8<sup>+</sup> T subpopulation showing a decrease in glycolysis upon activation and greater dependency on mitochondrial metabolism for cytokine production. Also, it was demonstrated that the binding affinity of specific antigens fine-tune T cell metabolism (217). Therefore, T lymphocyte insulin-receptor/GLUTs expression, insulin and glucose levels as well as, the affinity of antigens with cognate TCR of different T cell subsets all have implications to consider for therapeutic manipulation in the setting of hyperglycemia and hyperinsulinemia (T2D) and, during T-cell-mediated T1D featured by elevated glycemia and lack of insufficient insulin levels.

## Prolactin (PRL)

Prolactin is a pituitary hormone not only essential for reproduction and lactation but also involved in immunological responses. PRL and its receptor are expressed by various extra-pituitary tissues, including lymphoid cells (218, 219). PRL has a stimulatory action on the immune system; it affects differentiation and maturation of both, B and T lymphocytes, stimulates lymphocyte proliferation and macrophage function, and enhances inflammatory responses and production of immunoglobulins (220–222).

Increase serum PRL has been detected in autoimmune disorders including T1D and elevated prolactinemia was also



observed in T2D (223–225). The association between circulating PRL levels and glucose homeostasis has been controversial. Within the physiological range, higher serum PRL levels seem to be associated with insulin resistance in men (226) and with reduced glucose tolerance in the third trimester of pregnancy in women (227). Conversely, higher circulating PRL levels were associated with lower prevalence of diabetes and impaired glucose regulation in a large cohort of middle-aged and elderly men and postmenopausal women (228).

Experimental studies suggested a protective role associated with PRL modulation of T cell development; PRL reduces insulinitis and protects against autoimmune diabetes in NOD mice (229) in the autoimmune diabetes model induced by low-dose STZ administration in C57BL/6 mice (230). Further studies in this latter experimental model showed that PRL treatment enhances a Th2 response by increasing the frequency of IL-10 positive splenocytes and down-modulating the featured expression of the Th1 cytokines IFN- $\gamma$  and TNF- $\alpha$  in splenocytes (231). Furthermore, PRL-expanded Treg (CD4<sup>+</sup> Foxp3<sup>+</sup>) population and improved the efficacy of short-term low-dose anti-CD3 treatment (which induce a transient CD4<sup>+</sup> and CD8<sup>+</sup> T cell depletion) at achieving diabetes remission in the NOD mice (232). Conversely, severe hyperprolactinemia induced by anterior pituitary ectopic transplantation increases the incidence of diabetes in the NOD mice (233). A study analyzing the *in vitro* effect of PRL on CD4<sup>+</sup> T cell suggested that the modulatory effect is dose dependent; low-dose PRL promotes Th1 response through increases in its Th1-driven transcription factor T-bet, whereas higher doses have suppressive effects (234). Therefore, differences obtained in clinical and experimental studies might be explained on the basis of the PRL differential effect on T cells, glucose metabolism, and insulin resistance depending of the hormone concentration impacting on target tissues.

Moreover, it was demonstrated that PRL stimulates insulin secretion and proliferation of  $\beta$ -cells in murine and human islets (235–237) and in particular during pregnancy (238). Thus, a further protective action of PRL exerted at  $\beta$ -cells level could not be ruled out in the experimental models studied.

## Oxytocin (OXT)

Oxytocin is an essential neuropeptide involved in the regulation of maternal behavior, lactation, and parturition (239). In the central nervous system OXT is expressed in subpopulations of hypothalamic neurons, stored in the neurohypophysis and released into circulation. Besides its central origin, OXT is produced and released in peripheral tissues acting in a paracrine and autocrine fashion *via* widely expressed OXT receptors (240). In addition to the abovementioned physiological functions in mammals, the modulatory effect of the OXT-secreting system on immune system activity and metabolic homeostasis has come to gain attention.

Oxytocin effects on immune functions include thymus physiology, immunologic defense, homeostasis, and surveillance (241). However, scarce information exists regarding the interaction of OXT with T lymphocytes in diabetes. CD38, a membrane ADP-ribosyl cyclase expressed in several cells such as lymphocytes and  $\beta$ -cells, is involved in OXT secretion (242); targeted disruption of

CD38 accelerates autoimmune diabetes in NOD mice by enhancing autoimmunity (243). CD38-deficient mice presented a disbalance between T-effector and Treg cells and an age-dependent increase in a diabetogenic CD8 clonotype, along with impaired insulin secretion and an elevated plasma glucose level.

Recent studies have shown that the impairment of OXT signaling is associated with disturbance of metabolic homeostasis, resulting in obesity and diabetes. In mice under a high-fat diet, there was a significant increase in both OXT and OXT receptor levels in the brain, as well as an increase in OXT receptor in the islets (244). OXT receptor-deficient mice exhibited increase  $\beta$ -cell death under metabolic stress conditions resulting in impaired insulin secretion and glucose intolerance under a high-fat diet (244). Both OXT- and OXT receptor-deficient mice developed late-onset obesity (245, 246).

On the other hand, peripheral OXT treatment improved glucose tolerance and reduced food intake and visceral fat mass in mice under diet-induced obesity (247, 248). Moreover, OXT treatment improved glucose homeostasis and induced tissue regenerative changes of pancreatic islets after STZ-induced diabetes in rats (249); similar results were obtained in mice (248). Conversely, worsening of basal glycemia and glucose tolerance were observed under OXT treatment in ob/ob animals (250) suggesting that OXT effects on glucose metabolism may depend on the interaction with leptin signaling.

A central action of OXT on glucose homeostasis was also observed. Intranasal OXT delivery enhanced glucose tolerance and  $\beta$ -cell response in healthy men challenged with an oral glucose tolerance test (251). Furthermore, OXT nasal spray treatment in obese patients effectively reversed obesity and related lipid disorders and improved blood glucose and insulin postprandial levels (248). In addition, third-ventricle injections of OXT improved glucose intolerance and fasting blood insulin levels in mice under chronic high-fat diet feeding and led to significant improvements in glucose tolerance,  $\beta$ -cell insulin secretion, and blood insulin levels in the multiple low-doses administration of STZ-induced autoimmune diabetes in mice (248).

## Sexual Steroids

For most of autoimmune diseases, females are generally more frequently affected than males. This is the case for systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. However, sexual dimorphism in autoimmune diabetes prevalence is observed in NOD mice but not in humans (252). One of the main factors contributing to gender differences in immune system is sex hormones. The effects exerted by female (estrogen, progesterone) and male (androgens) steroid hormones on T lymphocytes might explain gender differences in specific autoimmune diseases (253).

Several studies indicate that testosterone has suppressive effects on T cells by inhibiting Th1 differentiation of naive CD4<sup>+</sup> T cells and pro-inflammatory cytokine production and enhancing the expression of anti-inflammatory cytokines (254, 255). Ovarian hormones also modulate T lymphocyte function. *In vivo* and *in vitro* evidence indicate that progesterone, which promotes maternal–fetal tolerance during pregnancy, favors the Th2, and suppresses Th1 and Th17 responses, and has a potent

Treg induction activity promoting the production of anti-inflammatory cytokines like TGF- $\beta$ 1 and IL-10 (256, 257). Numerous evidences support estrogens influence on the development and maintenance of thymic and peripheral T cell function with dual effects depending on factors, such as steroid concentration, target cell, and timing (258). Estradiol at periovulatory to pregnancy levels stimulates IL-4 and IL-10 production and inhibits TNF- $\alpha$  from CD4<sup>+</sup> T cells and increases Th2 and Treg phenotype, which might shift the immune response toward tolerance (258, 259). On the other hand, at lower concentrations, estradiol stimulates TNF- $\alpha$ , IFN- $\gamma$ , and IL-1 $\beta$  production (258, 260). Scarce information is available regarding sexual steroids and T cell interaction under the burden of diabetes.

NOD mice spontaneously develop diabetes with a strong female prevalence; a more invasive and destructive insulinitis, leading to an earlier onset and higher incidence is observed in females (261). Moreover, the incidence of diabetes was significantly decreased in female NOD mice, but increased in male, by castration at the time of weaning (262, 263). Furthermore, long-term administration of androgen or its derivatives to young female NOD mice resulted in a decrease in the percentage of CD4<sup>+</sup> T cells in peripheral blood mononuclear cells and the incidence of diabetes (264, 265). Bao and colleagues demonstrated that sex hormones modulate the Th1/Th2 balance in the early stages of the T cell-mediated autoimmune process in the NOD mice; IFN- $\gamma$  expression was significantly higher in pancreatic and lymph node-T cells from young females, whereas IL-4 expression was higher in male counterparts. This differential expression, enhancing Th1 immune response in female NOD mice, was found to be due to the upregulation of IL-12 induced IFN- $\gamma$  production through activation of STAT4 by estrogen (266). Additionally, it was suggested that male-specific gut microbiome play a protective role in NOD mice that is mediated, at least in part, *via* microbiota metabolism of sex hormones (267). Conversely, estradiol administration was found to restore immunomodulatory functions of iNKT cells and preserve female NOD mice from both spontaneous and cyclophosphamide-induced diabetes (268).

A clear sexual dimorphism is observed related to glucose metabolism and obesity-associated T2D. The sex difference in the prevalence of diabetes was reversed during reproductive life, there are more men with T2D at middle age while there are more affected women after menopause (269), suggesting a protective role of estrogens. Consistent with this observation, continuous estradiol treatment (pregnancy levels) in males inhibited weight gain and the associated onset of hyperglycemia in an islet amyloid (huIAPP)-dependent murine model of diabetes; histological analysis of the pancreas revealed estradiol prevented deposition of islet amyloid and preserved islet mass and  $\beta$ -cells insulin content (270). Mice of both sexes develop a vulnerability to STZ-induced insulin deficiency when estradiol production or signaling is genetically suppressed (aromatase-deficient, ArKO<sup>-/-</sup> and ER $\alpha$ -deficient, ERKO<sup>-/-</sup> mice); in these mice, estradiol treatment prevents STZ-induced  $\beta$ -cell death and helps sustain insulin production, and prevents diabetes (271). Estradiol protective effect on  $\beta$ -cells was also observed in isolated human pancreatic islets; estradiol treatment of cytokine-challenged islets increases islet viability by lowering NF- $\kappa$ B activity and caspase-9 activation and

cytokine-induced cell death. Additionally, estradiol improved glucose-stimulated insulin response *in vitro* and *in vivo* functionality of treated human islets after transplantation in the portal vein of STZ-induced NOD<sup>scid</sup> mice (272).

Estrogen protective action on glucose homeostasis is not only exerted in the pancreas; several studies indicated that estradiol enhances insulin sensitivity in peripheral tissues, improves body fat distribution, and reduces adipose tissue inflammation (273–275). Estrogen treatment prevented insulin insensitivity and reduced the expression of adipose tissue inflammation (*Mcp-1* and *Cd68*) induced by high-fat diet in ovariectomized mice (274).

Although its protective anti-inflammatory effect on immune cells, progesterone has been associated with the development of gestational diabetes. It was demonstrated that the hyperglycemic effect of gestational levels of progesterone is mostly due to the enhancement of insulin resistance (276), particularly by a reduction of glucose transporter 4 expression in skeletal muscle and adipose tissue (277) but also reducing insulin secretion by a non-genomic mechanism (278). A recent study performed in RINm5F  $\beta$ -cell line and primary rat islets show that progesterone, particularly at pharmacological concentrations used for preterm delivery prevention, induced apoptosis of pancreatic  $\beta$ -cells through an oxidative-stress-dependent mechanism (279), contributing to gestational diabetes pathogenesis.

It is well established the impact of testosterone deficiency on the development of visceral obesity and insulin resistance in men (280, 281). Consistently, androgen receptor-deficient mice exacerbates adiposity and insulin resistance induced by a high-fat diet; elevated serum IL-1 $\beta$  levels and decreased pancreatic glucose-stimulated insulin secretion was also observed (282). A recent transcriptome analysis of islets from adult male mice lacking androgen receptor selectively in  $\beta$ -cells revealed alterations in genes involved in inflammation and  $\beta$ -cell function (283).

Recently, Rubinow and colleagues analyzed lymphocyte subsets in subcutaneous adipose tissue biopsies after 4 weeks of pharmacological testosterone suppression with a GnRH receptor antagonist and controlled testosterone replacement in healthy male subjects. In this clinical study, change in serum total testosterone levels correlated inversely with CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells and ATMs within adipose tissue (275).

At the pancreas level, it was observed a sex specific protective action of testosterone on STZ-induced apoptosis in  $\beta$ -cells; the cytoprotective effect was seen in gonadectomized male but not in female rats (284, 285). Moreover, chronic hyperandrogenism induced  $\beta$ -cell dysfunction and failure to compensate high-fat diet induce insulin resistance in female mice (286). The sexual dimorphism in the modulation of glucose and energy homeostasis by testosterone is evidenced in the clinic, androgen excess predisposes to insulin resistance,  $\beta$ -cell dysfunction, and T2D in women (281). Nonetheless, further research is needed to reveal the mechanisms underlying the sex differences in the metabolic effect of testosterone.

## Neurotransmitters

Originally, the notion that neurotransmitters act as immunomodulators emerged with the discovery that their release from the nervous system could lead to signaling through lymphocyte

cell-surface receptors modulating immune response. It is now known that neurotransmitters can also be released from immune cells and act as autocrine or paracrine modulators.


It has been demonstrated that administration of gamma-aminobutyric acid (GABA), a major CNS neurotransmitter synthesized from glutamate by glutamic acid decarboxylase (GAD), exerts antidiabetic effects by acting on both islet  $\beta$ -cells and the immune system in both T1D and T2D models. GABA acts as an autocrine excitatory neurotransmitter in human pancreatic  $\beta$ -cells through GABA receptors (287, 288).

Gamma-aminobutyric acid promotes proliferation, protects  $\beta$ -cells from STZ- and cytokine-induced apoptosis (288), and inhibits human  $\beta$ -cell apoptosis following islet transplantation into NODscid mice (289). This protective effect is also observed *in vivo*, e.g., GABA treatment prevents insulinitis and diabetes onset and preserves insulin expression in NOD mice and in multiple low-dose STZ-induced diabetes in C57BL/6 mice

(288, 290, 291) and delays hyperglycemia in the adoptive transfer of disease in NODscid mice (292). Moreover, overtly diabetic NOD mice treated with GABA improved fasting glycemia, insulin and C-peptide levels and glucose tolerance (291).

Also, GABA receptors are expressed in various immune cells, including T cells (292, 293). Low doses of GABA inhibited activated T cell responses against islet autoantigens when assayed *ex vivo* (292), suggesting that GABA downregulates diabetogenic Teff function *in vivo*. Later studies showed an anti-inflammatory effect of GABA treatment, increasing the frequency and suppressive activity of splenic CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in pancreatic lymph nodes in NOD mice with no changes in GAD-reactive CD4<sup>+</sup> T cells and decreased circulating inflammatory cytokines in the multiple low-dose STZ-induced diabetes model (288, 291).

A beneficial effect of GABA was observed also in T2D experimental models. Oral GABA administration inhibited obesity, reduced fasting blood glucose, and improved glucose tolerance and



**FIGURE 1** | Schematic diagram depicts the interplay among T lymphocyte subsets, several types of hormones and neurotransmitters, and primary peripheral tissues regulating glucose metabolism and during the pathogenesis of diabetes.

insulin sensitivity in high-fat diet-fed C57BL/6 mice. Moreover, even after the onset of obesity and hyperglycemia, GABA treatment improved glucose homeostasis (294). Furthermore, GABA treatment inhibited obesity-related inflammation, reducing the frequency of VAT macrophage infiltrates and increasing the frequency of splenic CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in high-fat diet-fed mice (294).

In accordance with the antidiabetic effect in preclinical models, GABA and GABA analogs were also shown to exert insulinotropic effects in humans (295, 296).

Interestingly, consistent with the high levels of GAD found in the islets of Langerhans, GAD65 is one of the major target autoantigens recognized by self-reactive T cells in T1D. Complete suppression of  $\beta$ -cell GAD expression in NOD mice blocked the generation of diabetogenic T cells, protected islet grafts from autoimmune injury and consequently, the development of autoimmune diabetes (297). In fact, potential immunomodulation with GAD therapy has been extensively investigated for the prevention or treatment of T1D in humans (298).

Histamine is an inflammatory mediator classically involved in allergic reactions but also in the modulation of innate immunity and autoimmune reactions. Its diverse effects are mediated by the differential expression and regulation of four known histamine receptors (termed H1R-H4R) and their distinct intracellular signals (299). Th1 and Treg cells express relatively high levels of H1R, whereas H2R is preferentially expressed by Th2 cells. Histamine modulates T lymphocytes by enhancing Th1 responses through H1R and downregulates both the 1- and 2-type responses through H2R (300); activation of H1R by histamine decreases Treg cell suppressive functions.

The association of autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and diabetes, and elevated serum and tissue histamine levels was described many years ago (301–303). However, research searching for the possible role of histamine signaling on diabetes emerged recently.

In histidine decarboxylase (HDC) deficient NOD mice, the lack of endogenous histamine reduces IL-12 and IFN- $\gamma$  levels and delays the onset of autoimmune diabetes (304); the proportion CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> Treg cells in spleen and pancreatic lymph node remained unchanged. Surprisingly, exogenous histamine administration not only failed to increase the incidence of T1D but also delayed the onset of disease in both wild-type and HDC<sup>-/-</sup> mice (304).

Central histamine signaling is involved in the control of feeding behavior and energy homeostasis. H3R is principally expressed in histamine neurons and negatively regulates the synthesis and release of histamine. Treatment with a H3R agonist decreases appetite, body weight, and insulin resistance in diet-induced obese mice (305). On the other hand, targeted disruption of H3Rs leads to an obese phenotype (306). Moreover, mice deficient in histamine H1R or HDC showed a dysregulation in the leptin signaling, impaired glucose tolerance, and are prone to become obese on a high-fat diet or at advanced age (307–309).

It was recently reported that the H1R antagonist cetirizine partially counteracts cytokine- and oxidative stress-induced  $\beta$ -cell death (310). *In vivo*, H1R antagonist ameliorates high-fat diet-induced glucose intolerance in male C57BL/6 mice, but no effect was observed on diabetes outcome in female NOD mice, suggesting a protective effect of cetirizine against high-fat diet-induced  $\beta$ -cell dysfunction, but not against autoimmune  $\beta$ -cell destruction (311).

## CONCLUSION

T lymphocytes, as important components of the adaptive arm of the immune system, are key players in the modulation of metabolism in several tissues in health and disease (see **Figure 1**). The neuroendocrine system plays an essential role controlling the number and activity of different T cell subpopulations. Herein, we collected data that warrant further investigation on T lymphocytes biology hoping that it would lay the groundwork for future translational research that aims to restore homeostasis in metabolic disorders and treat diabetes in its multiple forms.

## AUTHOR CONTRIBUTIONS

LA and MP contributed to the conception and design of the review article and wrote sections of the manuscript; MG created the model figure. All authors contributed to manuscript revision, read and approved the submitted version.

## FUNDING

The present work was supported by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)-Argentina and FOCM-Mercosur Grant COF 03/11 to MP.

## REFERENCES

- Besedovsky H, del Rey A, Sorkin E, Da Prada M, Burri R, Honegger C. The immune response evokes changes in brain noradrenergic neurons. *Science* (1983) 221(4610):564–6. doi:10.1126/science.6867729
- Besedovsky H, del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. *Science* (1986) 233:652–4. doi:10.1126/science.3014662
- Blalock JE, Smith EM, Meyer WJ III. The pituitary-adrenocortical axis and the immune system. *Clin Endocrinol Metab* (1985) 14:1021–38. doi:10.1016/S0300-595X(85)80087-6
- Smith EM, Morrill AC, Meyer WJ III, Blalock JE. Corticotropin releasing factor induction of leukocyte-derived immunoreactive ACTH and endorphins. *Nature* (1986) 321(6073):881–2. doi:10.1038/321881a0
- Steinman L. Elaborate interactions between the immune and nervous systems. *Nat Immunol* (2004) 5:575–81. doi:10.1038/ni1078
- Savino W, Mendes-da-Cruz DA, Lepletier A, Dardenne M. Hormonal control of T-cell development in health and disease. *Nat Rev Endocrinol* (2016) 12(2):77–89. doi:10.1038/nrendo.2015.168
- Hotamisligil GS. Inflammation and metabolic disorders. *Nature* (2006) 444:860–7. doi:10.1038/nature05485
- Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKK $\beta$ /NF- $\kappa$ B and ER stress link overnutrition to energy imbalance and obesity. *Cell* (2008) 135:61–73. doi:10.1016/j.cell.2008.07.043
- Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. *Nat Med* (2009) 15(8):930–9. doi:10.1038/nm.2002



10. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, et al. Normalization of obesity-associated insulin resistance through immunotherapy. *Nat Med* (2009) 15:921–9. doi:10.1038/nm.2001
11. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. *Cell* (2010) 140:197–208. doi:10.1016/j.cell.2009.12.052
12. Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. *Nat Rev Endocrinol* (2012) 8(12):709–16. doi:10.1038/nrendo.2012.114
13. Khan IM, Perrard XY, Brunner G, Lui H, Sparks LM, Smith SR, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. *Int J Obes (Lond)* (2015) 39(11):1607–18. doi:10.1038/ijo.2015.104
14. International Diabetes Federation. *IDF Diabetes Atlas*. 8th ed. Brussels, Belgium: International Diabetes Federation (2017). Available from: <http://www.diabetesatlas.org>
15. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. *Clin Exp Immunol* (2009) 155(2):173–81. doi:10.1111/j.1365-2249.2008.03860.x
16. Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, et al. Insulinitis and  $\beta$ -cell mass in the natural history of type 1 diabetes. *Diabetes* (2016) 65(3):719–31. doi:10.2337/db15-0779
17. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. *Lancet* (2014) 383(9911):69–82. doi:10.1016/S0140-6736(13)60591-7
18. Cudworth AG, Woodrow JC. Letter: HL-A antigens and diabetes mellitus. *Lancet* (1974) 2:1153. doi:10.1016/S0140-6736(74)90930-1
19. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. *Curr Diab Rep* (2011) 11(6):533–42. doi:10.1007/s11892-011-0223-x
20. Bakay M, Pandey R, Hakonarson H. Genes involved in type 1 diabetes: an update. *Genes (Basel)* (2013) 4(3):499–521. doi:10.3390/genes4030499
21. Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. *Pediatr Diabetes* (2017) 19(3):346–53. doi:10.1111/pedi.12597
22. Sarvetnick N, Liggitt D, Pitts SL, Hansen SE, Stewart TA. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. *Cell* (1988) 52:773–82. doi:10.1016/0092-8674(88)90414-X
23. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. *J Exp Med* (1993) 178:87–99. doi:10.1084/jem.178.1.87
24. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? *Diabetes* (1994) 43:613–21. doi:10.2337/diab.43.5.613
25. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. *Science* (1995) 268:1185–8. doi:10.1126/science.7761837
26. Savinov AY, Wong FS, Chervonsky AV. IFN-gamma affects homing of diabetogenic T cells. *J Immunol* (2001) 167:6637–43. doi:10.4049/jimmunol.167.11.6637
27. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, et al. Autoreactive T cell responses show pro-inflammatory polarization in diabetes but a regulatory phenotype in health. *J Clin Invest* (2004) 113:451–63. doi:10.1172/JCI19585
28. Han D, Leyva CA, Matheson D, Mineo D, Messinger S, Blomberg BB, et al. Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. *Clin Immunol* (2011) 139:290–301. doi:10.1016/j.clim.2011.02.016
29. Zaccane P, Burton OT, Gibbs SE, Miller N, Jones FM, Schramm G, et al. The *S. mansoni* glycoprotein  $\alpha$ -1 induces Foxp3 expression in NOD mouse CD4<sup>+</sup> T cells. *Eur J Immunol* (2011) 41(9):2709–18. doi:10.1002/eji.201141429
30. Walker LS, von Herrath M. CD4 T cell differentiation in type 1 diabetes. *Clin Exp Immunol* (2016) 183(1):16–29. doi:10.1111/cei.12672
31. Arif S, Gibson VB, Nguyen V, Bingley PJ, Todd JA, Guy C, et al.  $\beta$ -cell specific T-lymphocyte response has a distinct inflammatory phenotype in children with Type 1 diabetes compared with adults. *Diabet Med* (2017) 34(3):419–25. doi:10.1111/dme.13153
32. Vukkadapu SS, Belli JM, Ishii K, Jegga AG, Hutton JJ, Aronow BJ, et al. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse. *Physiol Genomics* (2005) 21:201–11. doi:10.1152/physiolgenomics.00173.2004
33. Perone MJ, Bertera S, Shufesky WJ, Divito SJ, Montecalvo A, Mathers AR, et al. Suppression of autoimmune diabetes by soluble galectin-1. *J Immunol* (2009) 182(5):2641–53. doi:10.4049/jimmunol.0800839
34. Bending D, De la Peña H, Veldhoen M, Phillips JM, Uyttenhove C, Stockinger B, et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. *J Clin Invest* (2009) 119(3):565–72. doi:10.1172/JCI37865
35. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. *Eur J Immunol* (2009) 39:216–24. doi:10.1002/eji.200838475
36. Honkanen J, Nieminen JK, Gao R, Luopajarvi K, Salo HM, Ilonen J, et al. IL-17 immunity in human type 1 diabetes. *J Immunol* (2010) 185:1959–67. doi:10.4049/jimmunol.1000788
37. Liu SM, Lee DH, Sullivan JM, Chung D, Jäger A, Shum BO, et al. Differential IL-21 signaling in APCs leads to disparate Th17 differentiation in diabetes-susceptible NOD and diabetes-resistant NOD.Idd3 mice. *J Clin Invest* (2011) 121:4303–10. doi:10.1172/JCI46187
38. Li CR, Mueller EE, Bradley LM. Islet antigen-specific Th17 cells can induce TNF-alpha-dependent autoimmune diabetes. *J Immunol* (2014) 192:1425–32. doi:10.4049/jimmunol.1301742
39. Joseph J, Bittner S, Kaiser FM, Wiendl H, Kissler S. IL-17 silencing does not protect nonobese diabetic mice from autoimmune diabetes. *J Immunol* (2012) 188:216–21. doi:10.4049/jimmunol.1101215
40. Marwaha AK, Crome SQ, Panagiotopoulos C, Berg KB, Qin H, Ouyang Q, et al. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. *J Immunol* (2010) 185:3814–8. doi:10.4049/jimmunol.1001860
41. Arif S, Moore F, Marks K, Bouckennooghe T, Dayan CM, Planas R, et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. *Diabetes* (2011) 60:2112–9. doi:10.2337/db10-1643
42. Reinert-Hartwall L, Honkanen J, Salo HM, Nieminen JK, Luopajarvi K, Härkönen T, et al. Th1/Th17 plasticity is a marker of advanced beta cell autoimmunity and impaired glucose tolerance in humans. *J Immunol* (2015) 194:68–75. doi:10.4049/jimmunol.1401653
43. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. *Diabetologia* (1986) 29:63–7. doi:10.1007/BF02427283
44. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulinitis and  $\beta$ -cell loss in type 1 diabetes. *Nat Rev Endocrinol* (2009) 5:219–26. doi:10.1038/nrendo.2009.21
45. Grieco FA, Moore F, Vigneron F, Santin I, Villate O, Marselli L, et al. IL-17A increases the expression of proinflammatory chemokines in human pancreatic islets. *Diabetologia* (2014) 57(3):502–11. doi:10.1007/s00125-013-3135-2
46. Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. *Diabetes* (2011) 60(11):2903–13. doi:10.2337/db11-0090
47. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. *Nature* (2007) 448:480–3. doi:10.1038/nature05969
48. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. *Nature* (2007) 448:484–7. doi:10.1038/nature05970
49. Spolski R, Kashyap M, Robinson C, Yu Z, Leonard WJ. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. *Proc Natl Acad Sci U S A* (2008) 105:14028–33. doi:10.1073/pnas.0804358105
50. Sutherland AP, Van Belle T, Wurster AL, Suto A, Michaud M, Zhang D, et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. *Diabetes* (2009) 58:1144–55. doi:10.2337/db08-0882
51. Rydén AK, Perdue NR, Pagni PP, Gibson CB, Ratliff SS, Kirk RK, et al. Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes. *J Autoimmun* (2017) 84:65–74. doi:10.1016/j.jaut.2017.07.006

52. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. *Nature* (2000) 408:57–63. doi:10.1038/35040504
53. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. *Annu Rev Immunol* (2008) 26:57–79. doi:10.1146/annurev.immunol.26.021607.090316
54. Van Belle TL, Nierkens S, Arens R, von Herrath MG. Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. *Immunity* (2012) 36:1060–72. doi:10.1016/j.immuni.2012.04.005
55. Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. *Nat Rev Immunol* (2005) 5:853–65. doi:10.1038/nri1714
56. Regnell SE, Lernmark Å. Early prediction of autoimmune (type 1) diabetes. *Diabetologia* (2017) 60(8):1370–81. doi:10.1007/s00125-017-4308-1
57. Kenefeck R, Wang CJ, Kapadi T, Wardzinski L, Attridge K, Clough LE, et al. Follicular helper T cell signature in type 1 diabetes. *J Clin Invest* (2015) 125:292–303. doi:10.1172/JCI76238
58. Xu X, Shi Y, Cai Y, Zhang Q, Yang F, Chen H, et al. Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. *PLoS One* (2013) 8:e79858. doi:10.1371/journal.pone.0079858
59. Ferreira RC, Simons HZ, Thompson WS, Cutler AJ, Dopico XC, Smyth DJ, et al. IL-21 production by CD4 effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. *Diabetologia* (2015) 58:781–90. doi:10.1007/s00125-015-3509-8
60. Viisanen T, Ihanntola EL, Nääntö-Salonen K, Hyöty H, Nurminen N, Selvenius J, et al. Circulating CXCR5+PD-1+ICOS+ follicular T helper cells are increased close to the diagnosis of type 1 diabetes in children with multiple autoantibodies. *Diabetes* (2017) 66(2):437–47. doi:10.2337/db16-0714
61. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. *Int Immunol* (1998) 10(12):1969–80. doi:10.1093/intimm/10.12.1969
62. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. *Nat Rev Immunol* (2012) 12(3):180–90. doi:10.1038/nri3156
63. Todd JA, Aitman TJ, Cornall RJ, Ghosh S, Hall JR, Hearne CM, et al. Genetic analysis of autoimmune type 1 diabetes mellitus in mice. *Nature* (1991) 351:542–7. doi:10.1038/351542a0
64. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. *Nat Genet* (2007) 39:329–37. doi:10.1038/ng1958
65. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B, et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. *Am J Hum Genet* (2005) 76:773–9. doi:10.1086/429843
66. Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. *Nat Genet* (2007) 39:1074–82. doi:10.1038/ng2102
67. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat Genet* (2007) 39:857–64. doi:10.1038/ng2068
68. Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. *Nat Genet* (2009) 41:1011–5. doi:10.1038/ng.434
69. Schwedhelm K, Thorpe J, Murray SA, Gavin M, Speake C, Greenbaum C, et al. Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state. *Clin Immunol* (2017) 181:67–74. doi:10.1016/j.clim.2017.06.004
70. Todd JA, Evangelou M, Cutler AJ, Pekalski ML, Walker NM, Stevens HE, et al. Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial. *PLoS Med* (2016) 13(10):e1002139. doi:10.1371/journal.pmed.1002139
71. Lu J, Zhang C, Li L, Xue W, Zhang C, Zhang X. Unique features of pancreatic-resident regulatory T cells in autoimmune type 1 diabetes. *Front Immunol* (2017) 8:1235. doi:10.3389/fimmu.2017.01235
72. Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid tissues. *Nat Immunol* (2013) 14(10):1007–13. doi:10.1038/ni.2683
73. Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. *J Exp Med* (2004) 199(11):1479–89. doi:10.1084/jem.20040179
74. Kornete M, Sgouroudis E, Piccirillo CA. ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice. *J Immunol* (2012) 188(3):1064–74. doi:10.4049/jimmunol.1101303
75. Tan TG, Mathis D, Benoist C. Singular role for T-BET+CXCR3+ regulatory T cells in protection from autoimmune diabetes. *Proc Natl Acad Sci U S A* (2016) 113(49):14103–8. doi:10.1073/pnas.1616710113
76. Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. *Proc Natl Acad Sci U S A* (2003) 100(19):10878–83. doi:10.1073/pnas.1834400100
77. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. *Nat Rev Mol Cell Biol* (2008) 9(3):193–205. doi:10.1038/nrm2327
78. Lombardi A, Tomer Y. Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress. *J Autoimmun* (2017) 80:48–55. doi:10.1016/j.jaut.2017.02.002
79. Hansen JB, Tonnesen MF, Madsen AN, Hagedorn PH, Friberg J, Grunnet LG, et al. Divalent metal transporter 1 regulates iron-mediated ROS and pancreatic beta cell fate in response to cytokines. *Cell Metab* (2012) 16(4):449–61. doi:10.1016/j.cmet.2012.09.001
80. Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. *Nat Med* (1998) 4(7):781–5. doi:10.1038/nm0798-781
81. Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, Colvin SC, et al. Islet beta-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. *Diabetes* (2012) 61(4):818–27. doi:10.2337/db11-1293
82. Engin F, Yermalovich A, Nguyen T, Hummasti S, Fu W, Eizirik DL, et al. Restoration of the unfolded protein response in pancreatic beta cells protects mice against type 1 diabetes. *Sci Transl Med* (2013) 5(211):211ra156. doi:10.1126/scitranslmed.3006534
83. Meyerovich K, Ortis F, Allagnat F, Cardozo AK. Endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. *J Mol Endocrinol* (2016) 57(1):R1–17. doi:10.1530/JME-15-0306
84. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. *Science* (1993) 259(5091):87–91. doi:10.1126/science.7678183
85. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. *Diabetologia* (1997) 40:1286–92. doi:10.1007/s001250050822
86. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA* (2001) 286:327–34. doi:10.1001/jama.286.3.327
87. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-potsdam study. *Diabetes* (2003) 52:812–7. doi:10.2337/diabetes.52.3.812
88. Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. *Diabetes Care* (2009) 32:421–3. doi:10.2337/dc08-1161
89. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol* (2011) 11:98–107. doi:10.1038/nri2925
90. Nikolajczyk BS, Jagannathan-Bogdan M, Shin H, Gyurko R. State of the union between metabolism and the immune system in type 2 diabetes. *Genes Immun* (2011) 12:239–50. doi:10.1038/gene.2011.14
91. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue

- and is activated by free fatty acids via toll-like receptors 2 and 4 and JNK-dependent pathways. *J Biol Chem* (2007) 282:35279–92. doi:10.1074/jbc.M706762200
92. Ahmad R, Al-Mass A, Atizado V, Al-Hubail A, Al-Ghimlas F, Al-Arouj M, et al. Elevated expression of the toll-like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation. *J Inflamm (Lond)* (2012) 9(1):48. doi:10.1186/1476-9255-9-48
  93. Ehses J, Meier D, Wuest S, Rytka J, Boller S, Wielinga P, et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. *Diabetologia* (2010) 53:1795–806. doi:10.1007/s00125-010-1747-3
  94. Caricilli AM, Nascimento PH, Pauli JR, Tsukumo DM, Velloso LA, Carvalheira JB, et al. Inhibition of toll-like receptor 2 expression improves insulin sensitivity and signaling in muscle and white adipose tissue of mice fed a high-fat diet. *J Endocrinol* (2008) 199:399–406. doi:10.1677/JOE-08-0354
  95. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest* (2003) 112(12):1796–808. doi:10.1172/JCI200319246
  96. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest* (2003) 112(12):1821–30. doi:10.1172/JCI200319451
  97. Xia C, Rao X, Zhong J. Role of T lymphocytes in type 2 diabetes and diabetes-associated inflammation. *J Diabetes Res* (2017) 2017:6494795. doi:10.1155/2017/6494795
  98. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose-induced  $\beta$ -cell production of interleukin-1 $\beta$  contributes to glucotoxicity in human pancreatic islets. *J Clin Invest* (2002) 110:851–60. doi:10.1172/JCI200215318
  99. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, et al. Increased number of islet-associated macrophages in type 2 diabetes. *Diabetes* (2007) 56:2356–70. doi:10.2337/db06-1650
  100. Nackiewicz D, Dan M, He W, Kim R, Salmi A, Rütli S, et al. TLR2/6 and TLR4-activated macrophages contribute to islet inflammation and impair beta cell insulin gene expression via IL-1 and IL-6. *Diabetologia* (2014) 57(8):1645–54. doi:10.1007/s00125-014-3249-1
  101. Yin J, Peng Y, Wu J, Wang Y, Yao L. Toll-like receptor 2/4 links to free fatty acid-induced inflammation and  $\beta$ -cell dysfunction. *J Leukoc Biol* (2014) 95(1):47–52. doi:10.1189/jlb.0313143
  102. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J Clin Invest* (2007) 117:175–84. doi:10.1172/JCI29881
  103. Boutens L, Stienstra R. Adipose tissue macrophages: going off track during obesity. *Diabetologia* (2016) 59(5):879–94. doi:10.1007/s00125-016-3904-9
  104. Wu H, Ghosh S, Perrard XD, Feng L, Garcia GE, Perrard JL, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. *Circulation* (2007) 115:1029–38. doi:10.1161/CIRCULATIONAHA.106.638379
  105. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. *Arterioscler Thromb Vasc Biol* (2008) 28(7):1304–10. doi:10.1161/ATVBAHA.108.165100
  106. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, et al. CD8 $^{+}$  effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. *Nat Med* (2009) 15(8):914–20. doi:10.1038/nm.1964
  107. Rausch ME, Weisberg S, Vardhana P, Tortoriello DV. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. *Int J Obes (Lond)* (2008) 32(3):451–63. doi:10.1038/sj.ijo.0803744
  108. Rocha VZ, Folco EJ, Sukhova G, Shimizu K, Gotsman I, Vernon AH, et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. *Circ Res* (2008) 103(5):467–76. doi:10.1161/CIRCRESAHA.108.177105
  109. McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, et al. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. *Arterioscler Thromb Vasc Biol* (2014) 34(12):2637–43. doi:10.1161/ATVBAHA.114.304636
  110. Shirakawa K, Yan X, Shinmura K, Endo J, Kataoka M, Katsumata Y, et al. Obesity accelerates T cell senescence in murine visceral adipose tissue. *J Clin Invest* (2016) 126(12):4626–39. doi:10.1172/JCI88606
  111. Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, et al. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. *Immunity* (2012) 37(3):574–87. doi:10.1016/j.immuni.2012.06.016
  112. Lynch L, O'Shea D, Winter DC, Geoghegan J, Doherty DG, O'Farrelly C. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. *Eur J Immunol* (2009) 39:1893–901. doi:10.1002/eji.200939349
  113. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. *Annu Rev Immunol* (2007) 25:297–336. doi:10.1146/annurev.immunol.25.022106.141711
  114. Godfrey DI, Berzins SP. Control points in NKT-cell development. *Nat Rev Immunol* (2007) 7(7):505–18. doi:10.1038/nri2116
  115. Huh JY, Park J, Kim JI, Park YJ, Lee YK, Kim JB. Deletion of CD1d in adipocytes aggravates adipose tissue inflammation and insulin resistance in obesity. *Diabetes* (2017) 66(4):835–47. doi:10.2337/db16-1122
  116. Chehimi M, Vidal H, Eljaafari A. Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. *J Clin Med* (2017) 6(7):E68. doi:10.3390/jcm6070068
  117. Zeng C, Shi X, Zhang B, Liu H, Zhang L, Ding W, et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. *J Mol Med (Berl)* (2012) 90(2):175–86. doi:10.1007/s00109-011-0816-5
  118. Jagannathan-Bogdan M, McDonnell ME, Shin H, Rehman Q, Hasturk H, Apovian CM, et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. *J Immunol* (2011) 186(2):1162–72. doi:10.4049/jimmunol.1002615
  119. Winer S, Paltser G, Chan Y, Tsui H, Engleman E, Winer D, et al. Obesity predisposes to Th17 bias. *Eur J Immunol* (2009) 39(9):2629–35. doi:10.1002/eji.200838893
  120. Bertola A, Ciucci T, Rousseau D, Bourlier V, Duffaut C, Bonnafant S, et al. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. *Diabetes* (2012) 61(9):2238–47. doi:10.2337/db11-1274
  121. Zúñiga LA, Shen WJ, Joyce-Shaikh B, Pyatnova EA, Richards AG, Thom C, et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. *J Immunol* (2010) 185(11):6947–59. doi:10.4049/jimmunol.1001269
  122. Kolodin D, van Panhuys N, Li C, Magnuson AM, Cipolletta D, Miller CM, et al. Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. *Cell Metab* (2015) 21(4):543–57. doi:10.1016/j.cmet.2015.03.005
  123. Bapat SP, Myoung Suh J, Fang S, Liu S, Zhang Y, Cheng A, et al. Depletion of fat-resident Treg cells prevents age-associated insulin resistance. *Nature* (2015) 528(7580):137–41. doi:10.1038/nature16151
  124. Schmitz J, Evers N, Awazawa M, Nicholls HT, Brönneke HS, Dietrich A, et al. Obesogenic memory can confer long-term increases in adipose tissue but not liver inflammation and insulin resistance after weight loss. *Mol Metab* (2016) 5(5):328–39. doi:10.1016/j.molmet.2015.12.001
  125. Shirakawa K, Endo J, Katsumata Y, Yamamoto T, Kataoka M, Isobe S, et al. Negative legacy of obesity. *PLoS One* (2017) 12(10):e0186303. doi:10.1371/journal.pone.0186303
  126. Yanagisawa K, Yue S, van der Vliet HJ, Wang R, Alatrakchi N, Golden-Mason L, et al. Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C. *J Viral Hepat* (2013) 20(8):556–65. doi:10.1111/jvh.12081
  127. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H, et al. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. *J Exp Med* (1999) 189(12):1907–21. doi:10.1084/jem.189.12.1907
  128. Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, Kief B, et al. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. *J Clin Invest* (2015) 125(4):1752–62. doi:10.1172/JCI78941
  129. Rouxel O, Da Silva J, Beaudoin L, Nel I, Tard C, Cagninacci L, et al. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. *Nat Immunol* (2017) 18(12):1321–31. doi:10.1038/ni.3854



130. Hiejima E, Kawai T, Nakase H, Tsuruyama T, Morimoto T, Yasumi T, et al. Reduced numbers and proapoptotic features of mucosal-associated invariant T cells as a characteristic finding in patients with inflammatory bowel disease. *Inflamm Bowel Dis* (2015) 21(7):1529–40. doi:10.1097/MIB.0000000000000397
131. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. *Nature* (2008) 455(7216):1109–13. doi:10.1038/nature07336
132. Kostic AD, Gevers D, Siljander H, Vatanen T, Hyötyläinen T, Hämäläinen AM, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. *Cell Host Microbe* (2015) 17(2):260–73. doi:10.1016/j.chom.2015.01.001
133. Yu H, Gagliani N, Ishigame H, Huber S, Zhu S, Esplugues E, et al. Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development. *Proc Natl Acad Sci U S A* (2017) 114(39):10443–8. doi:10.1073/pnas.1705599114
134. Mariño E, Richards JL, McLeod KH, Stanley D, Yap YA, Knight J, et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. *Nat Immunol* (2017) 18(5):552–62. doi:10.1038/ni.3713
135. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care* (2009) 32(Suppl 2):S157–63. doi:10.2337/dc09-S302
136. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. *Nat Med* (2012) 18(3):363–74. doi:10.1038/nm.2627
137. Fink LN, Costford SR, Lee YS, Jensen TE, Bilan PJ, Oberbach A, et al. Pro-inflammatory macrophages increase in skeletal muscle of high fat-fed mice and correlate with metabolic risk markers in humans. *Obesity (Silver Spring)* (2014) 22(3):747–57. doi:10.1002/oby.20615
138. Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. *Diabetes* (2009) 58(11):2525–35. doi:10.2337/db08-1261
139. Khan IM, Dai Perrard XY, Perrard JL, Mansoori A, Smith CW, Wu H, et al. Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency. *Atherosclerosis* (2014) 233(2):419–28. doi:10.1016/j.atherosclerosis.2014.01.011
140. Jiang E, Perrard XD, Yang D, Khan IM, Perrard JL, Smith CW, et al. Essential role of CD11a in CD8+ T-cell accumulation and activation in adipose tissue. *Arterioscler Thromb Vasc Biol* (2013) 34:34–43. doi:10.1161/ATVBAHA.113.302077
141. Zhao C, Wang Z, Robertson MW, Davies JD. Cachexia in the non-obese diabetic mouse is associated with CD4+ T-cell lymphopenia. *Immunology* (2008) 125(1):48–58. doi:10.1111/j.1365-2567.2008.02819.x
142. Stentz FB, Kitabchi AE. Transcriptome and proteome expressions involved in insulin resistance in muscle and activated T-lymphocytes of patients with type 2 diabetes. *Genomics Proteomics Bioinformatics* (2007) 5(3–4):216–35. doi:10.1016/S1672-0229(08)60009-1
143. Schiaffino S, Pereira MG, Ciciliot S, Rovere-Querini P. Regulatory T cells and skeletal muscle regeneration. *FEBS J* (2017) 284(4):517–24. doi:10.1111/febs.13827
144. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). *Nat Rev Immunol* (2014) 14(6):377–91. doi:10.1038/nri3667
145. Bergan-Roller HE, Sheridan MA. The growth hormone signaling system: insights into coordinating the anabolic and catabolic actions of growth hormone. *Gen Comp Endocrinol* (2017) 258:119–33. doi:10.1016/j.ygcen.2017.07.028
146. Weigent DA. Lymphocyte GH-axis hormones in immunity. *Cell Immunol* (2013) 285(1–2):118–32. doi:10.1016/j.cellimm.2013.10.003
147. Davoodi-Semiromi A, Laloraya M, Kumar GP, Purohit S, Jha RK, She JX. A mutant Stat5b with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice. *J Biol Chem* (2004) 279(12):11553–61. doi:10.1074/jbc.M312110200
148. Murawski MR, Litherland SA, Clare-Salzler MJ, Davoodi-Semiromi A. Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. *Ann N Y Acad Sci* (2006) 1079:198–204. doi:10.1196/annals.1375.031
149. Villares R, Kakabadse D, Juarranz Y, Gomariz RP, Martínez-A C, Mellado M. Growth hormone prevents the development of autoimmune diabetes. *Proc Natl Acad Sci U S A* (2013) 110(48):E4619–27. doi:10.1073/pnas.1314985110
150. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the national cooperative growth study experience. *J Clin Endocrinol Metab* (1996) 81:1704–10. doi:10.1210/jcem.81.5.8626820
151. Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. *Lancet* (2000) 355:610–3. doi:10.1016/S0140-6736(99)04055-6
152. Child CJ, Zimmermann AG, Scott RS, Cutler GB Jr, Battelino T, Blum WF, et al. Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program. *J Clin Endocrinol Metab* (2011) 96:E1025–34. doi:10.1210/jc.2010-3023
153. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. *Endocr Rev* (2009) 30:152–77. doi:10.1210/er.2008-0027
154. Bonfig W, Molz K, Woelfle J, Hofer SE, Hauffa BP, Schoenau E, et al. Metabolic safety of growth hormone in type 1 diabetes and idiopathic growth hormone deficiency. *J Pediatr* (2013) 163(4):1095–8.e4. doi:10.1016/j.jpeds.2013.04.045
155. Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. *Ann Pediatr Endocrinol Metab* (2017) 22(3):145–52. doi:10.6065/apem.2017.22.3.145
156. de Mello Coelho V, Villa-Verde DM, Farias-de-Oliveira DA, de Brito JM, Dardenne M, Savino W. Functional insulin-like growth factor-1/insulin-like growth factor-1 receptor-mediated circuit in human and murine thymic epithelial cells. *Neuroendocrinology* (2002) 75(2):139–50. doi:10.1159/000048230
157. Bergerot I, Fabien N, Maguer V, Thivolet C. Insulin-like growth factor-1 (IGF-1) protects NOD mice from insulinitis and diabetes. *Clin Exp Immunol* (1995) 102:335–40. doi:10.1111/j.1365-2249.1995.tb03786.x
158. Kaino Y, Hirai H, Ito T, Kida K. Insulin-like growth factor I (IGF-I) delays the onset of diabetes in non-obese diabetic (NOD) mice. *Diabetes Res Clin Pract* (1996) 34:7–11. doi:10.1016/S0168-8227(96)01326-5
159. Chen W, Salojin KV, Mi QS, Grattan M, Meagher TC, Zucker P, et al. Insulin-like growth factor (IGF)-I/IGF-binding protein-3 complex: therapeutic efficacy and mechanism of protection against type 1 diabetes. *Endocrinology* (2004) 145(2):627–38. doi:10.1210/en.2003-1274
160. Anguela XM, Tafuro S, Roca C, Callejas D, Agudo J, Obach M, et al. Nonviral-mediated hepatic expression of IGF-I increases Treg levels and suppresses autoimmune diabetes in mice. *Diabetes* (2013) 62(2):551–60. doi:10.2337/db11-1776
161. Bilbao D, Luciani L, Johannesson B, Piszczek A, Rosenthal N. Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease. *EMBO Mol Med* (2014) 6(11):1423–35. doi:10.15252/emmm.201303376
162. George M, Ayuso E, Casellas A, Costa C, Devedjian JC, Bosch F. Beta cell expression of IGF-I leads to recovery from type 1 diabetes. *J Clin Invest* (2002) 109:1153–63. doi:10.1172/JCI0212969
163. Casellas A, Salavert A, Agudo J, Ayuso E, Jimenez V, Moya M, et al. Expression of IGF-I in pancreatic islets prevents lymphocytic infiltration and protects mice from type 1 diabetes. *Diabetes* (2006) 55:3246–55. doi:10.2337/db06-0328
164. Agudo J, Ayuso E, Jimenez V, Salavert A, Casellas A, Tafuro S, et al. IGF-I mediates regeneration of endocrine pancreas by increasing beta cell replication through cell cycle protein modulation in mice. *Diabetologia* (2008) 51:1862–72. doi:10.1007/s00125-008-1087-8
165. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. *Annu Rev Immunol* (2000) 18:309–45. doi:10.1146/annurev.immunol.18.1.309
166. Mittelstadt PR, Monteiro JP, Ashwell JD. Thymocyte responsiveness to endogenous glucocorticoids is required for immunological fitness. *J Clin Invest* (2012) 122(7):2384–94. doi:10.1172/JCI63067
167. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. *Mol Cell Endocrinol* (2011) 335(1):2–13. doi:10.1016/j.mce.2010.04.005
168. Londono P, Komura A, Hara N, Zipris D. Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes. *Clin Immunol* (2010) 135(3):401–11. doi:10.1016/j.clim.2010.01.007



169. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. *Pharmacol Ther* (2002) 96(1):23–43. doi:10.1016/S0163-7258(02)00297-8
170. Fauci AS, Dale DC. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. *J Clin Invest* (1974) 3:240. doi:10.1172/JCI107544
171. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. *J Leukoc Biol* (1996) 60:563. doi:10.1002/jlb.60.5.563
172. Wieggers GJ, Labeur MS, Stec IE, Klinkert WE, Holsboer F, Reul JM. Glucocorticoids accelerate anti-T cell receptor-induced T cell growth. *J Immunol* (1995) 155(4):1893–902.
173. Wieggers GJ, Stec IE, Klinkert WE, Reul JM. Glucocorticoids regulate TCR-induced elevation of CD4: functional implications. *J Immunol* (2000) 164(12):6213–20. doi:10.4049/jimmunol.164.12.6213
174. Ramirez F, McKnight AJ, Silva A, Mason D. Glucocorticoids induce the expression of CD8 alpha chains on concanavalin A-activated rat CD4+ T cells: induction is inhibited by rat recombinant interleukin 4. *J Exp Med* (1992) 176(6):1551–9. doi:10.1084/jem.176.6.1551
175. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. *Proc Natl Acad Sci U S A* (2004) 101(1):227–32. doi:10.1073/pnas.0300372101
176. Barcala Tabarozzi AE, Andreone L, Deckers J, Castro CN, Gimeno ML, Ariolfo L, et al. GR-independent down-modulation on GM-CSF bone marrow-derived dendritic cells by the selective glucocorticoid receptor modulator compound A. *Sci Rep* (2016) 6:36646. doi:10.1038/srep36646
177. De Bosscher K, Vanden Berghe W, Beck IM, Van Molle W, Hennuyer N, Hapgood J, et al. A fully dissociated compound of plant origin for inflammatory gene repression. *Proc Natl Acad Sci U S A* (2005) 102:15827–32. doi:10.1073/pnas.0505541102
178. Liberman AC, Antunica-Noguero M, Ferraz-de-Paula V, Palermo-Neto J, Castro CN, Druker J, et al. Compound A, a dissociated glucocorticoid receptor modulator, inhibits T-bet (Th1) and induces GATA-3 (Th2) activity in immune cells. *PLoS One* (2012) 7(4):e35155. doi:10.1371/journal.pone.0035155
179. WHO. *Improving Preterm Birth Outcomes. Executive Summary*. Geneva: WHO (2015).
180. Lindsay RS, Lindsay RM, Waddell BJ, Seckl JR. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone. *Diabetologia* (1996) 39:1299–305. doi:10.1007/s001250050573
181. Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenol-pyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. *J Clin Invest* (1998) 101:2174–81. doi:10.1172/JCI1567
182. De Blasio MJ, Dodic M, Jefferies AJ, Moritz KM, Wintour EM, Owens JA. Maternal exposure to dexamethasone or cortisol in early pregnancy differentially alters insulin secretion and glucose homeostasis in adult male sheep offspring. *Am J Physiol Endocrinol Metab* (2007) 293(1):E75–82. doi:10.1152/ajpendo.00689.2006
183. Kelly BA, Lewandowski AJ, Worton SA, Davis EF, Lazdam M, Francis J, et al. Antenatal glucocorticoid exposure and long-term alterations in aortic function and glucose metabolism. *Pediatrics* (2012) 129(5):e1282–90. doi:10.1542/peds.2011-3175
184. Diepenbruck I, Much CC, Krumbholz A, Kolster M, Thieme R, Thieme D, et al. Effect of prenatal steroid treatment on the developing immune system. *J Mol Med (Berl)* (2013) 91(11):1293–302. doi:10.1007/s00109-013-1069-2
185. Gieras A, Gehbauer C, Perna-Barrull D, Engler JB, Diepenbruck I, Glau L, et al. Prenatal administration of betamethasone causes changes in the T cell receptor repertoire influencing development of autoimmunity. *Front Immunol* (2017) 8:1505. doi:10.3389/fimmu.2017.01505
186. Greene NH, Pedersen LH, Liu S, Olsen J. Prenatal prescription corticosteroids and offspring diabetes: a national cohort study. *Int J Epidemiol* (2013) 42(1):186–93. doi:10.1093/ije/dys228
187. Gesina E, Tronche F, Herrera P, Duchene B, Tales W, Czernichow P, et al. Dissecting the role of glucocorticoids on pancreas development. *Diabetes* (2004) 53(9):2322–9. doi:10.2337/diabetes.53.9.2322
188. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. *Nature* (2001) 409(6817):194–8. doi:10.1038/35051587
189. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. *Nat Rev Neurosci* (2001) 2(8):551–60. doi:10.1038/35086018
190. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. *J Clin Invest* (2004) 114(1):57–66. doi:10.1172/JCI200421134
191. Lee JH, Patel K, Tae HJ, Lustig A, Kim JW, Mattson MP, et al. Ghrelin augments murine T-cell proliferation by activation of the phosphatidylinositol-3-kinase, extracellular signal-regulated kinase and protein kinase C signaling pathways. *FEBS Lett* (2014) 588(24):4708–19. doi:10.1016/j.febslet.2014.10.044
192. Dixit VD, Yang H, Sun Y, Weeraratna AT, Youm YH, Smith RG, et al. Ghrelin promotes thymopoiesis during aging. *J Clin Invest* (2007) 117(10):2778–90. doi:10.1172/JCI30248
193. Dixit VD, Yang H, Cooper-Jenkins A, Giri BB, Patel K, Taub DD. Reduction of T cell-derived ghrelin enhances proinflammatory cytokine expression: implications for age-associated increases in inflammation. *Blood* (2009) 113(21):5202–5. doi:10.1182/blood-2008-09-181255
194. Baena-Nieto G, Lomas-Romero IM, Mateos RM, Leal-Cosme N, Perez-Arana G, Aguilar-Diosdado M, et al. Ghrelin mitigates  $\beta$ -cell mass loss during insulinitis in an animal model of autoimmune diabetes mellitus, the BioBreeding/Worcester rat. *Diabetes Metab Res Rev* (2017) 33(1):1–13. doi:10.1002/dmrr.2813
195. Orlova EG, Shirshov SV, Loginova OA. Leptin and ghrelin regulate dendritic cell maturation and dendritic cell induction of regulatory T-cells. *Dokl Biol Sci* (2015) 462:171–4. doi:10.1134/S001249661503014X
196. Friedman JM. Leptin, leptin receptors, and the control of body weight. *Nutr Rev* (1998) 56(2 Pt 2):s38–46; discussion s54–75. doi:10.1111/j.1753-4887.1998.tb01685.x
197. Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. *Proc Natl Acad Sci U S A* (1996) 93(25):14564–8. doi:10.1073/pnas.93.25.14564
198. Bouloumié A, Drexler HC, Lafontan M, Busse R. Leptin, the product of Ob gene, promotes angiogenesis. *Circ Res* (1998) 83(10):1059–66. doi:10.1161/01.RES.83.10.1059
199. Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. *Nat Genet* (1996) 12(3):318–20. doi:10.1038/ng0396-318
200. Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. *J Immunol* (2005) 174(6):3137–42. doi:10.4049/jimmunol.174.6.3137
201. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. *Nature* (1998) 394(6696):897–901. doi:10.1038/29795
202. Lord GM, Matarese G, Howard JK, Bloom SR, Lechler RI. Leptin inhibits the anti-CD3-driven proliferation of peripheral blood T cells but enhances the production of proinflammatory cytokines. *J Leukoc Biol* (2002) 72(2):330–8.
203. Matarese G, Sanna V, Lechler RI, Sarvetnick N, Fontana S, Zappacosta S, et al. Leptin accelerates autoimmune diabetes in female NOD mice. *Diabetes* (2002) 51(5):1356–61. doi:10.2337/diabetes.51.5.1356
204. Lee CH, Reifsnyder PC, Naggert JK, Wasserfall C, Atkinson MA, Chen J, et al. Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: I. Pathophysiological analysis. *Diabetes* (2005) 54(9):2525–32. doi:10.2337/diabetes.54.9.2525
205. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? *J Clin Endocrinol Metab* (2001) 86(7):3257–65. doi:10.1210/jcem.86.7.7623
206. Viardot A, Grey ST, Mackay F, Chisholm D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. *Endocrinology* (2007) 148(1):346–53. doi:10.1210/en.2006-0686
207. Viardot A, Heilbronn LK, Samocha-Bonet D, Mackay F, Campbell LV, Samaras K. Obesity is associated with activated and insulin resistant immune cells. *Diabetes Metab Res Rev* (2012) 28(5):447–54. doi:10.1002/dmrr.2302

208. Otton R, Soriano FG, Verlengia R, Curi R. Diabetes induces apoptosis in lymphocytes. *J Endocrinol* (2004) 182(1):145–56. doi:10.1677/joe.0.1820145
209. Pedersen DJ, Guilherme A, Danaei LV, Heyda L, Matevossian A, Cohen J, et al. A major role of insulin in promoting obesity-associated adipose tissue inflammation. *Mol Metab* (2015) 4(7):507–18. doi:10.1016/j.molmet.2015.04.003
210. Martinez-Sanchez ME, Hiriart M, Alvarez-Buylla ER. The CD4+ T cell regulatory network mediates inflammatory responses during acute hyperinsulinemia: a simulation study. *BMC Syst Biol* (2017) 11(1):64. doi:10.1186/s12918-017-0436-y
211. Han JM, Patterson SJ, Speck M, Ehses JA, Levings MK. Insulin inhibits IL-10-mediated regulatory T cell function: implications for obesity. *J Immunol* (2014) 192(2):623–9. doi:10.4049/jimmunol.1302181
212. Helderman JH, Strom TB. Specific insulin binding site on T and B lymphocytes as a marker of cell activation. *Nature* (1978) 274(5666):62–3. doi:10.1038/274062a0
213. Brown TJ, Ercolani L, Ginsberg BH. Properties and regulation of the T lymphocyte insulin receptor. *J Recept Res* (1983) 3:481–94. doi:10.3109/10799898309041854
214. Fischer HJ, Sie C, Schumann E, Witte AK, Dressel R, van den Brandt J, et al. The insulin receptor plays a critical role in T cell function and adaptive immunity. *J Immunol* (2017) 198(5):1910–20. doi:10.4049/jimmunol.1601011
215. Frauworth KA, Riley JL, Harris MH, Parry RV, Rathmel JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. *Immunity* (2002) 16(6):769–77. doi:10.1016/S1074-7613(02)00323-0
216. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. *J Immunol* (2008) 180(7):4476–86. doi:10.4049/jimmunol.180.7.4476
217. Jones N, Cronin JG, Dolton G, Panetti S, Schauenburg AJ, Galloway SAE, et al. Metabolic adaptation of human CD4+ and CD8+ T-cells to T-cell receptor-mediated stimulation. *Front Immunol* (2017) 8:1516. doi:10.3389/fimmu.2017.01516
218. Pellegrini I, Lebrun JJ, Ali S, Kelly PA. Expression of prolactin and its receptor in human lymphoid cells. *Mol Endocrinol* (1992) 6(7):1023–31. doi:10.1210/me.6.7.1023
219. Hawkins TA, Gala RR, Dunbar JC. The lymphocyte and macrophage profile in the pancreas and spleen of NOD mice: percentage of interleukin-2 and prolactin receptors on immunocompetent cell subsets. *J Reprod Immunol* (1996) 32(1):55–71. doi:10.1016/S0165-0378(96)00986-2
220. Spangelo BL, Hall NR, Ross PC, Goldstein AL. Stimulation of in vivo antibody production and concanavalin-A-induced mouse spleen cell mitogenesis by prolactin. *Immunopharmacology* (1987) 14(1):11–20. doi:10.1016/0162-3109(87)90004-X
221. Bernton EW, Meltzer MS, Holaday JW. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. *Science* (1988) 239(4838):401–4. doi:10.1126/science.3122324
222. Gala RR, Shevach EM. Influence of prolactin and growth hormone on the activation of dwarf mouse lymphocytes in vivo. *Proc Soc Exp Biol Med* (1993) 204(2):224–30. doi:10.3181/00379727-204-43657
223. Mooradian AD, Morley JE, Billington CJ, Slag MF, Elson MK, Shafer RB. Hyperprolactinemia in male diabetics. *Postgrad Med J* (1985) 61(711):11–4. doi:10.1136/pgmj.61.711.11
224. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. *Autoimmun Rev* (2007) 6(8):537–42. doi:10.1016/j.autrev.2006.10.005
225. Arnold E, Rivera JC, Thebault S, Moreno-Páramo D, Quiroz-Mercado H, Quintanar-Stéphano A, et al. High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. *Diabetes* (2010) 59(12):3192–7. doi:10.2337/db10-0873
226. Daimon M, Kamba A, Murakami H, Mizushiri S, Osonoi S, Yamaichi M, et al. Association between serum prolactin levels and insulin resistance in non-diabetic men. *PLoS One* (2017) 12(4):e0175204. doi:10.1371/journal.pone.0175204
227. Ekinci EI, Torkamani N, Ramchand SK, Churilov L, Sikaris KA, Lu ZX, et al. Higher maternal serum prolactin levels are associated with reduced glucose tolerance during pregnancy. *J Diabetes Investig* (2017) 8(5):697–700. doi:10.1111/jdi.12634
228. Wang T, Lu J, Xu Y, Li M, Sun J, Zhang J, et al. Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. *Diabetes Care* (2013) 36(7):1974–80. doi:10.2337/dc12-1893
229. Atwater I, Gundos B, DiBartolomeo R, Bazaes R, Jovanovic L. Pregnancy hormones prevent diabetes and reduce lymphocytic infiltration of islets in the NOD mouse. *Ann Clin Lab Sci* (2002) 32:87–92.
230. Holstad M, Sandler S. Prolactin protects against diabetes induced by multiple low doses of streptozotocin in mice. *J Endocrinol* (1999) 163(2):229–34. doi:10.1677/joe.0.1630229
231. Lau J, Börjesson A, Holstad M, Sandler S. Prolactin regulation of the expression of TNF-alpha, IFN-gamma and IL-10 by splenocytes in murine multiple low dose streptozotocin diabetes. *Immunol Lett* (2006) 102(1):25–30. doi:10.1016/j.imlet.2005.06.006
232. Hyslop CM, Tsai S, Shrivastava V, Santamaria P, Huang C. Prolactin as an adjunct for type 1 diabetes immunotherapy. *Endocrinology* (2016) 157(1):150–65. doi:10.1210/en.2015-1549
233. Hawkins TA, Gala RR, Dunbar JC. Prolactin modulates the incidence of diabetes in male and female NOD mice. *Autoimmunity* (1994) 18(3):155–62. doi:10.3109/08916939409007991
234. Tomio A, Schust DJ, Kawana K, Yasugi T, Kawana Y, Mahalingaiah S, et al. Prolactin can modulate CD4+ T-cell response through receptor-mediated alterations in the expression of T-bet. *Immunol Cell Biol* (2008) 86(7):616–21. doi:10.1038/icb.2008.29
235. Sorenson RL, Brelje TC, Roth C. Effects of steroid and lactogenic hormones on islets of Langerhans: a new hypothesis for the role of pregnancy steroids in the adaptation of islets to pregnancy. *Endocrinology* (1993) 133:2227–34. doi:10.1210/endo.133.5.8404674
236. Stout LE, Svensson AM, Sorenson RL. Prolactin regulation of islet-derived INS-1 cells: characteristics and immunocytochemical analysis of STAT5 translocation. *Endocrinology* (1997) 138(4):1592–603. doi:10.1210/endo.138.4.5089
237. Freemark M, Avril I, Fleenor D, Driscoll P, Petro A, Opara E, et al. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. *Endocrinology* (2002) 143(4):1378–85. doi:10.1210/endo.143.4.8722
238. Huang C, Snider F, Cross JC. Prolactin receptor is required for normal glucose homeostasis and modulation of beta-cell mass during pregnancy. *Endocrinology* (2009) 150:1618–26. doi:10.1210/en.2008-1003
239. Burbach JP, Luckman SM, Murphy D, Gainer H. Gene regulation in the magnocellular hypothalamo-neurohypophyseal system. *Physiol Rev* (2001) 81(3):1197–267. doi:10.1152/physrev.2001.81.3.1197
240. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. *Physiol Rev* (2001) 81(2):629–83. doi:10.1152/physrev.2001.81.2.629
241. Wang P, Yang HP, Tian S, Wang L, Wang SC, Zhang F, et al. Oxytocin-secreting system: a major part of the neuroendocrine center regulating immunologic activity. *J Neuroimmunol* (2015) 289:152–61. doi:10.1016/j.jneuroim.2015.11.001
242. Jin D, Liu HX, Hirai H, Torashima T, Nagai T, Lopatina O, et al. CD38 is critical for social behaviour by regulating oxytocin secretion. *Nature* (2007) 446(7131):41–5. doi:10.1038/nature05526
243. Chen J, Chen YG, Reifsnnyder PC, Schott WH, Lee CH, Osborne M, et al. Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP ribosyltransferase 2-dependent fashion. *J Immunol* (2006) 176(8):4590–9. doi:10.4049/jimmunol.176.8.4590
244. Watanabe S, Wei FY, Matsunaga T, Matsunaga N, Kaitsuka T, Tomizawa K. Oxytocin protects against stress-induced cell death in murine pancreatic  $\beta$ -cells. *Sci Rep* (2016) 6:25185. doi:10.1038/srep25185
245. Takayanagi Y, Kasahara Y, Onaka T, Takahashi N, Kawada T, Nishimori K. Oxytocin receptor-deficient mice developed late-onset obesity. *Neuroreport* (2008) 19(9):951–5. doi:10.1097/WNR.0b013e3283021ca9
246. Camerino C. Low sympathetic tone and obese phenotype in oxytocin-deficient mice. *Obesity (Silver Spring)* (2009) 17(5):980–4. doi:10.1038/oby.2009.12
247. Maejima Y, Iwasaki Y, Yamahara Y, Kodaira M, Sedbazar U, Yada T. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. *Aging (Albany NY)* (2011) 3(12):1169–77. doi:10.18632/aging.100408
248. Zhang H, Wu C, Chen Q, Chen X, Xu Z, Wu J, et al. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. *PLoS One* (2013) 8(5):e61477. doi:10.1371/journal.pone.0061477

249. Elabd SK, Sabry I, Mohasseb M, Algendy A. Oxytocin as a novel therapeutic option for type I diabetes and diabetic osteopathy. *Endocr Regul* (2014) 48(2):87–102. doi:10.4149/endo\_2014\_02\_87
250. Altirriba J, Poher AL, Caillon A, Arsenijevic D, Veyrat-Durebex C, Lyautey J, et al. Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes. *Endocrinology* (2014) 155(11):4189–201. doi:10.1210/en.2014-1466
251. Klement J, Ott V, Rapp K, Brede S, Piccinini F, Cobelli C, et al. Oxytocin improves  $\beta$ -cell responsiveness and glucose tolerance in healthy men. *Diabetes* (2017) 66(2):264–71. doi:10.2337/db16-0569
252. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. *Front Neuroendocrinol* (2014) 35(3):347–69. doi:10.1016/j.yfrne.2014.04.004
253. Ortona E, Pierdominici M, Maselli A, Veroni C, Aloisi F, Shoenfeld Y. Sex-based differences in autoimmune diseases. *Ann Ist Super Sanita* (2016) 52(2):205–12. doi:10.4415/ANN\_16\_02\_12
254. Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. *Proc Natl Acad Sci U S A* (2014) 111(27):9887–92. doi:10.1073/pnas.1402468111
255. Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on the immune system. *Cell Immunol* (2015) 294(2):87–94. doi:10.1016/j.cellimm.2015.02.004
256. Li X, Wang B, Li Y, Wang L, Zhao X, Zhou X, et al. The Th1/Th2/Th17/Treg paradigm induced by stachydrine hydrochloride reduces uterine bleeding in RU486-induced abortion mice. *J Ethnopharmacol* (2013) 145(1):241–53. doi:10.1016/j.jep.2012.10.059
257. Tan JJ, Peeva E, Zandman-Goddard G. Hormonal modulation of the immune system – a spotlight on the role of progestogens. *Autoimmun Rev* (2015) 14(6):536–42. doi:10.1016/j.autrev.2015.02.004
258. Straub RH. The complex role of estrogens in inflammation. *Endocr Rev* (2007) 28(5):521–74. doi:10.1210/er.2007-0001
259. Prieto GA, Rosenstein Y. Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. *Immunology* (2006) 118(1):58–65. doi:10.1111/j.1365-2567.2006.02339.x
260. Gilmore W, Weiner LP, Correale J. Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. *J Immunol* (1997) 158(1):446–51.
261. Kachapati K, Adams D, Bednar K, Ridgway WM. The non-obese diabetic (NOD) mouse as a model of human type 1 diabetes. *Methods Mol Biol* (2012) 933:3–16. doi:10.1007/978-1-62703-068-7\_1
262. Fitzpatrick F, Lepault F, Homo-Delarche F, Bach JF, Dardenne M. Influence of castration, alone or combined with thymectomy, on the development of diabetes in the nonobese diabetic mouse. *Endocrinology* (1991) 129(3):1382–90. doi:10.1210/endo-129-3-1382
263. Rosmalen JG, Pigman MJ, Kersseboom R, Drexhage HA, Leenen PJ, Homo-Delarche F. Sex steroids influence pancreatic islet hypertrophy and subsequent autoimmune infiltration in nonobese diabetic (NOD) and NODscid mice. *Lab Invest* (2001) 81(2):231–9. doi:10.1038/labinvest.3780231
264. Fox HS. Androgen treatment prevents diabetes in nonobese diabetic mice. *J Exp Med* (1992) 175(5):1409–12. doi:10.1084/jem.175.5.1409
265. Toyoda H, Takei S, Formby B. Effect of 5- $\alpha$  dihydrotestosterone on T-cell proliferation of the female nonobese diabetic mouse. *Proc Soc Exp Biol Med* (1996) 213(3):287–93. doi:10.3181/00379727-213-44060
266. Bao M, Yang Y, Jun HS, Yoon JW. Molecular mechanisms for gender differences in susceptibility to T cell-mediated autoimmune diabetes in nonobese diabetic mice. *J Immunol* (2002) 168(10):5369–75. doi:10.4049/jimmunol.168.10.5369
267. Markle JG, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolfe-Kampczyk U, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. *Science* (2013) 339(6123):1084–8. doi:10.1126/science.1233521
268. Gourdy P, Bourgeois EA, Levescot A, Pham L, Riant E, Ahui ML, et al. Estrogen therapy delays autoimmune diabetes and promotes the protective efficiency of natural killer T-cell activation in female nonobese diabetic mice. *Endocrinology* (2016) 157(1):258–67. doi:10.1210/en.2015-1313
269. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* (2004) 27(5):1047–53. doi:10.2337/diacare.27.10.2569-a
270. Geisler JG, Zawulich W, Zawulich K, Lakey JR, Stukenbrok H, Milici AJ, et al. Estrogen can prevent or reverse obesity and diabetes in mice expressing human islet amyloid polypeptide. *Diabetes* (2002) 51(7):2158–69. doi:10.2337/diabetes.51.7.2158
271. Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. *Proc Natl Acad Sci U S A* (2006) 103(24):9232–7. doi:10.1073/pnas.0602956103
272. Contreras JL, Smyth CA, Bilbao G, Young CJ, Thompson JA, Eckhoff DE. 17 $\beta$ -Estradiol protects isolated human pancreatic islets against proinflammatory cytokine-induced cell death: molecular mechanisms and islet functionality. *Transplantation* (2002) 74(9):1252–9. doi:10.1097/00007890-200211150-00010
273. Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. *Endocr Rev* (2013) 34(3):309–38. doi:10.1210/er.2012-1055
274. Shen M, Kumar SP, Shi H. Estradiol regulates insulin signaling and inflammation in adipose tissue. *Horm Mol Biol Clin Investig* (2014) 17(2):99–107. doi:10.1515/hmbci-2014-0007
275. Rubinow KB, Chao JH, Hagman D, Kratz M, Van Yserloo B, Gaikwad NW, et al. Circulating sex steroids coregulate adipose tissue immune cell populations in healthy men. *Am J Physiol Endocrinol Metab* (2017) 313(5):E528–39. doi:10.1152/ajpendo.00075.2017
276. Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. *Am J Clin Nutr* (2000) 71(5 Suppl):1256S–61S. doi:10.1093/ajcn/71.5.1256S
277. Sugaya A, Sugiyama T, Yanase S, Shen XX, Minoura H, Toyoda N. Expression of glucose transporter 4 mRNA in adipose tissue and skeletal muscle of ovariectomized rats treated with sex steroid hormones. *Life Sci* (2000) 66(7):641–8. doi:10.1016/S0024-3205(99)00636-0
278. Straub SG, Sharp GW, Meglasson MD, De Souza CJ. Progesterone inhibits insulin secretion by a membrane delimited, non-genomic action. *Biosci Rep* (2001) 21(5):653–66. doi:10.1023/A:1014773010350
279. Nunes VA, Portioli-Sanches EP, Rosim MP, Araujo MS, Praxedes-Garcia P, Valle MM, et al. Progesterone induces apoptosis of insulin-secreting cells: insights into the molecular mechanism. *J Endocrinol* (2014) 221(2):273–84. doi:10.1530/JOE-13-0202
280. Yu IC, Lin HY, Sparks JD, Yeh S, Chang C. Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. *Diabetes* (2014) 63(10):3180–8. doi:10.2337/db13-1505
281. Navarro G, Allard C, Xu W, Mauvais-Jarvis F. The role of androgens in metabolism, obesity, and diabetes in males and females. *Obesity (Silver Spring)* (2015) 23(4):713–9. doi:10.1002/oby.21033
282. Dubois V, Laurent MR, Jardi F, Antonio L, Lemaire K, Goyvaerts L, et al. Androgen deficiency exacerbates high-fat diet-induced metabolic alterations in male mice. *Endocrinology* (2016) 157(2):648–65. doi:10.1210/en.2015-1713
283. Xu W, Niu T, Xu B, Navarro G, Schipma MJ, Mauvais-Jarvis F. Androgen receptor-deficient islet  $\beta$ -cells exhibit alteration in genetic markers of insulin secretion and inflammation. A transcriptome analysis in the male mouse. *J Diabetes Complications* (2017) 31(5):787–95. doi:10.1016/j.jdiacomp.2017.03.002
284. Morimoto S, Mendoza-Rodríguez CA, Hiriart M, Larrieta ME, Vital P, Cerbón MA. Protective effect of testosterone on early apoptotic damage induced by streptozotocin in rat pancreas. *J Endocrinol* (2005) 187(2):217–24. doi:10.1677/joe.1.06357
285. Palomar-Morales M, Morimoto S, Mendoza-Rodríguez CA, Cerbón MA. The protective effect of testosterone on streptozotocin-induced apoptosis in beta cells is sex specific. *Pancreas* (2010) 39(2):193–200. doi:10.1097/MPA.0b013e3181c156d9
286. Navarro G, Xu W, Jacobson DA, Wicksteed B, Allard C, Zhang G, et al. Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male. *Cell Metab* (2016) 23(5):837–51. doi:10.1016/j.cmet.2016.03.015
287. Braun M, Ramracheya R, Bengtsson M, Clark A, Walker JN, Johnson PR, et al. Gamma-aminobutyric acid (GABA) is an autocrine excitatory transmitter in human pancreatic beta-cells. *Diabetes* (2010) 59(7):1694–701. doi:10.2337/db09-0797



288. Soltani N, Qiu H, Aleksic M, Glinka Y, Zhao F, Liu R, et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. *Proc Natl Acad Sci U S A* (2011) 108(28):11692–7. doi:10.1073/pnas.1102715108
289. Tian J, Dang H, Chen Z, Guan A, Jin Y, Atkinson MA, et al. Gamma-aminobutyric acid regulates both the survival and replication of human  $\beta$ -cells. *Diabetes* (2013) 62(11):3760–5. doi:10.2337/db13-0931
290. Beales PE, Hawa M, Williams AJ, Albertini MC, Giorgini A, Pozzilli P. Baclofen, a gamma-aminobutyric acid-b receptor agonist, delays diabetes onset in the non-obese diabetic mouse. *Acta Diabetol* (1995) 32(1):53–6. doi:10.1007/BF00581047
291. He S, Zhang Y, Wang D, Tao K, Zhang S, Wei L, et al. Rapamycin/GABA combination treatment ameliorates diabetes in NOD mice. *Mol Immunol* (2016) 73:130–7. doi:10.1016/j.molimm.2016.01.008
292. Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. *J Immunol* (2004) 173(8):5298–304. doi:10.4049/jimmunol.173.8.5298
293. Alam S, Laughton DL, Walding A, Wolstenholme AJ. Human peripheral blood mononuclear cells express GABAA receptor subunits. *Mol Immunol* (2006) 43:1432–42. doi:10.1016/j.molimm.2005.07.025
294. Tian J, Dang HN, Yong J, Chui WS, Dizon MP, Yaw CK, et al. Oral treatment with gamma-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. *PLoS One* (2011) 6(9):e25338. doi:10.1371/journal.pone.0025338
295. Cavagnini F, Pinto M, Dubini A, Invitti C, Cappelletti G, Polli EE. Effects of gamma aminobutyric acid (GABA) and muscimol on endocrine pancreatic function in man. *Metabolism* (1982) 31(1):73–7. doi:10.1016/0026-0495(82)90029-4
296. Passariello N, Giugliano D, Torella R, Sgambato S, Coppola L, Frascolla N. A possible role of gamma-aminobutyric acid in the control of the endocrine pancreas. *J Clin Endocrinol Metab* (1982) 54(6):1145–9. doi:10.1210/jcem-54-6-1145
297. Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH, et al. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. *Science* (1999) 284(5417):1183–7. doi:10.1126/science.284.5417.1183
298. Ryden AK, Wesley JD, Coppieters KT, Von Herrath MG. Non-antigenic and antigenic interventions in type 1 diabetes. *Hum Vaccin Immunother* (2014) 10(4):838–46. doi:10.4161/hv.26890
299. O'Mahony L, Akdis M, Akdis CA. Regulation of the immune response and inflammation by histamine and histamine receptors. *J Allergy Clin Immunol* (2011) 128(6):1153–62. doi:10.1016/j.jaci.2011.06.051
300. Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OA, Malolepszy J, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. *Nature* (2001) 413(6854):420–5. doi:10.1038/35096564
301. Frewin DB, Cleland LG, Jonsson JR, Robertson PW. Histamine levels in human synovial fluid. *J Rheumatol* (1986) 13(1):13–4.
302. Gill DS, Barradas MA, Fonseca VA, Dandona P. Plasma histamine concentrations are elevated in patients with diabetes mellitus and peripheral vascular disease. *Metabolism* (1989) 38(3):243–7. doi:10.1016/0026-0495(89)90082-6
303. Tuomisto L, Kilpeläinen H, Riekkinen P. Histamine and histamine-N-methyltransferase in the CSF of patients with multiple sclerosis. *Agents Actions* (1983) 13(2–3):255–7. doi:10.1007/BF01967346
304. Alkan M, Machavoine F, Rignault R, Dam J, Dy M, Thieblemont N. Histidine decarboxylase deficiency prevents autoimmune diabetes in NOD mice. *J Diabetes Res* (2015) 2015:965056. doi:10.1155/2015/965056
305. Yoshimoto R, Miyamoto Y, Shimamura K, Ishihara A, Takahashi K, Kotani H, et al. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. *Proc Natl Acad Sci U S A* (2006) 103(37):13866–71. doi:10.1073/pnas.0506104103
306. Takahashi K, Suwa H, Ishikawa T, Kotani H. Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. *J Clin Invest* (2002) 110(12):1791–9. doi:10.1172/JCI15784
307. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. *Diabetes* (2001) 50(2):385–91. doi:10.2337/diabetes.50.2.385
308. Fülöp AK, Földes A, Buzás E, Hegyi K, Miklós IH, Romics L, et al. Hyperleptinemia, visceral adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene. *Endocrinology* (2003) 144(10):4306–14. doi:10.1210/en.2003-0222
309. Masaki T, Chiba S, Yasuda T, Noguchi H, Kakuma T, Watanabe T, et al. Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. *Diabetes* (2004) 53(9):2250–60. doi:10.2337/diabetes.53.9.2250
310. Anvari E, Fred RG, Welsh N. The H1-receptor antagonist cetirizine protects partially against cytokine- and hydrogen peroxide-induced  $\beta$ -TC6 cell death in vitro. *Pancreas* (2014) 43(4):624–9. doi:10.1097/MPA.0000000000000076
311. Anvari E, Wang X, Sandler S, Welsh N. The H1-receptor antagonist cetirizine ameliorates high-fat diet-induced glucose intolerance in male C57BL/6 mice, but not diabetes outcome in female non-obese diabetic (NOD) mice. *Ups J Med Sci* (2015) 120(1):40–6. doi:10.3109/03009734.2014.967422

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Andreone, Gimeno and Perone. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.